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Abstract 
It has been shown that the heati rate varies not only in relation to the cardiac demand 
but is also affected by the presence of cardiac disease and diabetes. Furthermore, it has 
been shown that heart rate variability may be used as an early indicator of cardiac 
disease susceptibility and the presence of diabetes. Therefore, the heati rate variability 
may be used for early clinical screening of these diseases. In order to reliably assess the 
patient's condition, the heati rate variability infolTIlation is determined from an 
electrocardiogram data acquisition system. Once collected, the heati rate variability 
signal is characterised and used as a basis for classification. 
This study details the development of a heart rate variability data acquisition system, 
method of collecting known patient data, and design of a signal-processing algorithm 
that characterises heart rate variability infolTIlation to be used as a basis for patient 
classification. Specifically, six sets of 5 minute electrocardiogram signals are collected 
by a personal computer based data acquisition system in a clinical setting. Consecutive 
R-wave deflections are detected from the electrocardiogram and used to determine the 
individual heart beat intervals. The outlying measurements are then removed and the 
remaining data is interpolated. The processed data is then characterised using time-
frequency analysis and specific features are determined. Lastly, these features are used 
as a basis in a classification system. The results are then compared to the known patient 
conditions and the effectiveness of the screening procedure is detelTIlined. 
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Chapter 1 - Introduction 
1.1. Objectives 
The primary objective of this work is to research the effectiveness of a clinical system 
for an expedient, non-invasive, screening of patient susceptibility to coronary heart 
disease (CHD) and the presence of diabetic mellitus (DM). Specifically, this work seeks 
to accomplish the following specific objectives. 
• In order to research the effectiveness of the proposed screening system, a 
computer based, clinical data acquisition (DAQ) system for collecting 
electrocardiogram (ECG), respiration, and arterial blood pressure (ABP) data is 
designed and implemented. The system not only acquires the patient's 
physiological wavefolU1s, but also stores the patient's physical dimensions, 
medical history, and laboratOlY results in order to confirm the patient's known 
condition and later assess the system's screening performance. The system also 
incorporates a clinical methodology in order to evoke a response from the 
patient's cardiac system, specifically, a change in the patient's heart rate (HR). 
• Various signal processing algorithms are investigated and applied to the patient 
heart rate variability (HRV) signal, which is derived from the ECG signal. The 
objective is to research which algOlithms best distinguish between diseased and 
normal patients. Fmthermore, additional algorithms are investigated and applied 
to the patient respiration and ABP infonnation in order to research if additional 
physiological information provides for enhanced patient screening for the 
presence ofDM and CHD. 
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• The effectiveness of the proposed screening system is researched by comparing 
the screening results to the known patient conditions. Specifically, the clinical 
screening system classifies a patient as normal (N) or having DM, CHD, or 
diabetic coronalY heali disease (CHDD). The screening perfomlance is assessed 
using the common medical statistics of sensitivity, specificity, positive 
predictive value and negative predictive value. 
1.2. Thesis Outline 
Chapter 1 presents the thesis objectives and provides a background of the physiological 
processes that regulate HRV. Cunent research related to HRV is also presented as well 
as analysis methods for characterising and classify physiological signals. 
Chapter 2 provides details of the clinical DAQ system. Specifically, the clinical 
methodology for collecting the patient data is described. Additionally, the hardware 
components are explained and the custom-written DAQ and utility programmes are 
presented. 
Chapter 3 discusses the bio-signal processing algorithm to extract HRV from ECG. In 
paliicular, the chapter presents the detection of the cardiac cycles in the ECG signal and 
the method of computing the HR for each beat. Considerations of removing possible 
outlier data are discussed as well as methods for removing the HRV signal trend. 
Chapter 4 presents various methods and algorithms to analyse the HRV signal. 
Specifically, time domain based methods, frequency domain based methods, and time-
frequency based methods are applied to the HRV signals of several sample patients and 
then compared. These analyses are later used as a basis for patient classification. 
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Chapter 5 presents the bio-signal processing algorithms for ABP analyses. The systolic 
and diastolic cyclic pressure limits are extracted from the ABP signal. Furthermore, the 
maximum change in pressure per cardiac cycle and the QA interval, which is an ABP-
ECG data fusion algorithm, is presented and applied to several sample patients. Similar 
to HRV analyses, these analyses are later used as a basis for patient classification. 
Chapter 6 compares the results of classification based upon various analyses features. In 
pmiicular, patients with known conditions are used to train a classification system using 
supervised leaming. The trained classification system is then tested on the patients and 
the classification error is compared for each set of features. 
Chapter 7 provides a summary of the observations and conclusions of this research. 
Original contributions by the author are itemised and suggestions for future 
investigations are discussed. 
1.3. Diabetes Mellitus 
Diabetes Mellitus (DM) is characterised by abnOlmal, elevated blood glucose 
concentrations and is categorised into two types. Type I DM is a severe, chronic f011n of 
diabetes caused by insufficient production of insulin and resulting in abnormal 
metabolism of carbohydrates, fats, and proteins. Type I DM typically appears in 
childhood or adolescence, and is fatal if untreated. Type I DM is characterised by not 
only increased glucose levels in the blood and urine, but also excessive thirst, frequent 
urination, acidosis, and wasting. Type I DM is also called insulin-dependent diabetes. 
[1] 
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More common than Type I, is the Type II DM fOID1 of diabetes that typically appears in 
adulthood and also called non-insulin-dependent diabetes. In the United States of 
America (USA), there are over 10 million diagnosed cases with an estimated 5.9 million 
Americans who are unaware they are diabetic. Of the diagnosed cases of DM, 90% are 
Type II DM. [2] [3] In the United Arab Emirates (UAE) 19% of the people over 20 
years of age is diabetic. Furthermore, 50% of all patients treated in hospitals of the UAE 
were unaware they were diabetic. [4] Also in the Arabian Gulf, it has been recorded that 
15% of the Omani population is diabetic. [5] Beyond the Gulf, the World Health 
Organisation (WHO) estimates 135 million diabetics [6] and in the future, the US 
Centre for Disease Control (CDC) estimates an increase of Type II DM of 165% over 
the next 50 years. [7] The Emirates Medical Association's Diabetes Society estimates 
50% of the UAE population will be diabetic within the next 25 years. [8] 
Complications due to DM contribute to over 200,000 deaths in America per year. [9] 
Complications include blindness, kidney failure, retinopathy, neuropathy, and disability 
when amputation is necessary. Fmihennore, DM is the leading cause of heart disease 
and stroke. In fact, diabetic cardiovascular disease (DCVD) is the leading cause of death 
for people with OM, who are 2 to 4 times more likely to suffer heart trouble than people 
without DM. Additionally, 70% of diabetic patients are more likely to die prematurely if 
they experience a heart attack. [10] 
Common symptoms of DM include frequent urination, extreme thirst, unexplained 
weight loss, bluned vision, frequency or reoccuning skin, gum or bladder infections, 
unusual fatigue or drowsiness and occasionally, numbness or tingling in the hands and 
feet. However, many OM patients experience no symptoms at all. Traditional clinical 
diagnosis involves a routine of monitoring the blood glucose levels over several hours 
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in response to glucose ingestion. Of course, this test does not indicate the progression of 
the disease or presence of diabetic complications. [11] 
1.4. Diabetic Autonomic Neuropathy 
Diabetic autonomic neuropathy (DAN), as defined by the 1988 San Antonio (Texas) 
consensus meeting, is a descriptive term restricted to disorders in the autonomic nervous 
system, manifesting as dysfunction of several organ systems. [12] Specifically, DAN is 
nerve damage caused by decreased blood flow and high blood-glucose levels. 
Autonomic neuropathies affect the nerves that regulate involuntary vital functions, such 
as the HR, digestion, and metabolism. The prevalence of observable neuropathy among 
diagnosed diabetics approaches 60%. [13] 
DAN encompasses disturbances in reflex arcs involving one or more sensors, an 
afferent branch, a central processing unit, an efferent branch and neuromuscular 
junctions. [14] Symptoms of DAN are vague, non-specific and signs are difficult to 
detect, except in advanced stages of the disease. Even so, DAN is associated with 
increased morbidity and mOliality with nephropathy, cardiac arrhythmias, myocardial 
ischaemia and sudden cardiac death all associated with DAN. [15] [16] 
Diagnosis of DAN involves the Autonomic Function Tests (AFT) [17] recommended by 
the San Antonio (Texas 1988) consensus meeting. The tests include HR and Arterial 
Blood Pressure (ABP) responses to standing up, HR response to deep breathing, ABP 
response to sustained handgrip, HR response to Valsava manoeuvre, and spectral 
analysis ofHR and ABP variability. 
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Success of a test in clinical practice depends on many factors that usually differ from 
accepted research tests. The clinical procedure must incorporate simplicity, which is a 
non-complex methodology that may be canied out by one person and requires minimal 
patient cooperation. The procedure must also be safe and entails no unnecessary risk to 
the patient. Lastly, the procedure must be cost effective, reproducible, time efficient, 
and have easily interpretable results. 
When assessing DAN using the AFT HR response to sustained handgrip, the following 
methodology is used. First, the maximum patient handgrip contraction is determined 
and then the patient is requested to sustain a hand grip of 30% of maximum contraction 
for up to 5 minutes. ABP is measured every minute, and the difference between the 
diastolic blood pressure before the release of the handgrip and the start of the test is 
taken as the measure of the response. However, the response is related to the strength of 
contraction and has a strong gender influence. Moreover, adequate performance is 
beyond the ability of many diabetic and elderly subjects. [18] The test is cumbersome 
and of limited use in a practical clinical setting. 
HR and ABP responses to Valsava manoeuvre are complex and difficult to perfonn in a 
clinical environment. The procedure consists of forced expiration to a set pressure 
against a closed expiratory route. There is an initial rise in the ABP and a baroreceptor 
reflex (BR) mediated decrease in HR. The BR refers to bio-sensors that detect pressure 
in the aOliic arch and carotid arteries. With a decrease in HR, a fall in ABP occurs, 
followed by an increase in HR and thus a recovery of the ABP. Immediately after the 
termination of the test, there is a transient increase in ABP, leading to a fall in HR. 
Needless to say, this complex response is difficult to index and use as an assessment of 
DAN. Therefore, both the Valsava manoeuvre and ABP response to sustained hand grip 
were not considered in this study. 
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Requesting a patient to change from a horizontal (supine) position to a vertical 
(standing) position brings the influence of gravity on the circulatory system, and thus, a 
greater cardiac load. With an increased load, the ABP decreases which causes an 
increase in HR due to the BR reflex. Lastly, with an increase in HR, the ABP increases. 
This is then followed by a decrease in the HR, for nonnal patients. This AFT test is 
easily implemented by requesting the patient to lie quietly (supine) for at least 
5 minutes, then stand up unaided as quickly as possible, and remain standing thereafter 
for another 5 minutes. The test is objective, reproducible and does not depend on age or 
resting HR. Furthem10re; this test has been proven to detect the earliest physiological 
changes in approximately two thirds ofDM patients. [19] [20] 
The HR response to deep breathing is also used as an AFT, and is termed respiratOlY 
sinus a11'hythmia (RSA). The RSA is measured by requiring the patient to lie quietly and 
breathe deeply at a specified rate, which produces maximum variations in HR. In most 
studies RSA is quantified as the mean ratio between the maximum and minimum HR 
during consecutive deep breaths (HRMAX / HRM1N). However, there is no consensus on 
the exact clinical method or how the response is quantified. [21] 
1.5. Coronary Heart Disease 
CHD and Cardiovascular Disease (CVD) include various dysfunctions of the circulatOlY 
system, and accounts, by far, for the greatest cause of morbidity in the USA, as shown 
in the 1996 morbidity statistics of Figure 1.1. [22] In the UAE, CVD mOliality 
accounted for 25% of all deaths in the year 2000, and 49% of all non-communicable 
diseases. [23] 
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Figure 1.1 lists OM mortality separate from CVD mortality, and the number of CVO 
deaths with OM as the underlying cause is not recorded. [24] However, it is known that 
OM patients are 2 to 4 times more likely to develop CVO than non-OM patients. In the 
UAE, 43% of OM diagnosed patients are recorded in the CVO mortality statistics. [25] 
Similarly in the USA, CVO accounts for 65% of OM deaths. [26] 
Cardiovascular Disease 
All Cancer 
Unintentinoal Injures 
Chronic Obstructive Pulmonary Disease 
Pneumonia and Influenza 
Diabetes Mellitus 
Suicide 
HIV 
Homicide 
All Other Cases 
Figure 1.1: USA Mortality in 1996. 
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Early detection of CHO prior to clinical events, coupled with implementations of 
preventive management strategies, can delay the progression of the disease. In fact, 
proper diet, physical exercise, cessation of smoking, control of blood pressure and 
reduced cholesterol lowers a patients odds of myocardial infarction by 19 times, as 
shown in Figure 1.2. [27] [28] 
Primmy screening of CHO involves the Exercise ECG Test, which, if positive, is 
followed by coronmy angiography to diagnose CHO. This test involves monitoring the 
25 
l2-lead ECG signal while the patient is requested to perfOlm an increasing physical 
activity, usually moderated by a treadmill. Specifically, the test begins with the patient 
at a slow anaerobic pace and ends with an aerobic run. Throughout the procedure, the 
clinical technician monitors the ECG morphology, checks for ectopic beats, and notes 
the presence of cardiac arrhythmia. Based upon the results, the patient is recommended 
for angiography in order to confilm the presence of CHD. 
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Figure 1.2: Comparison of myocardial infarction risk given known patient condition. 
However, recent studies have shown the Exercise ECG Test to be a poor indicator of the 
presence of CHD in patients. A recent JAMA publication has shown that patients who 
receive angiography have far less incidents of myocardial infarction than those patients 
who pass the Exercise ECG Test. [29] [30] On a personal note, the author's father-in-
law suffered a myocardial infarction five months after an Exercise ECG screening 
indicated no presence of CHD. Some have suggested augmenting the screening through 
analysis of the HRV for improved diagnosis. [31] Even so, many disabled, obese and 
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elderly patients are not able to perfom1 the physical requirements of the Exercise ECG 
screening. Thus, another simple and low-cost clinical screening of CHD is required. 
1.6. Non-Invasive Physiological Signals 
With the development of cost-effective computers and DAQ systems, use of non-
invasive physiological signals for clinical diagnosis and screening has increased greatly. 
[32] Physiological signals include mechanical measurements of ABP, respiratory 
pressure, bladder pressure, blood flow, heart sounds, and body temperature. 
Physiological signals also include electrical measurements of ECG, 
electroencephalogram (EEG), electromyogram (EMG), galvanic skin response (GSR), 
and many other electrical signals of the body. Beyond this, new systems are being 
developed for clinical chemical measurements of blood oxygen and carbon dioxide 
saturation through the use of infrared light reflection and absorption. [33] From these 
physiological measurements, secondalY measurements are computed, such as 
respiration from the respiratOlY pressure and HR from ECG or ABP signals. Non-
invasive measurements minimise risk of infection, require no analgesics, and reduce 
measurement artefact due to patient stress, such as adrenalin and hypertension. 
Currently, most non-invasive physiological measurements are analysed directly by the 
clinical physician or technician. However, with the advancement of low-cost 
computational power, the clinical diagnosis may be efficiently automated in order to 
screen more patients in a workday, reduce the screening cost, and minimise the 
possibility of misdiagnosis due to human error. 
The process of automating the clinical diagnosis involves acquisition of the 
physiological signal, characterisation of the signal through analysis and feature 
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extraction, and, lastly, classification of the patient condition, as displayed in Figure l.3. 
The type of signal analysis and feature selection employed depends empirically on 
which best highlights the differences between n01TI1al and diseased patients. 
Classification is implemented through traditional clustering based upon the Euclidian 
distance or by neural networks (NN), both of which are discussed later in this chapter. 
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Figure 1.3: Algorithm for analysing and classifying a physiological signal. 
Signal analysis may be categorised into time-based analysis, frequency-based analysis, 
and time-frequency based analysis. Time-based analysis involves the application of 
mathematical procedures directly to the measured physiological samples. Frequency-
based analysis involves first translating the measurements into the frequency domain 
where analysis of the power spectrum is perfo1TI1ed. Time-Frequency analysis involves 
analysis of the power spectrum while preserving the time information of the 
physiological measurements. The best analysis method for characterising the signal is 
the one that provides the best classification. 
1.6.1. Time-Based Analysis 
Statistical analysis of the measured physiological signal is commonly used to 
characterise the signal for categorising the patient condition. The most common 
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statistical analysis algorithms are the mean and standard deviation (STD), as defined in 
Equation 1.1. The mean computation detenl1ines the average value while the STD 
determines the spread or breadth of the signal values. Since most physiological 
measurements are sampled and represented as numerical values in a computer, the 
sample mean and sample STD are used to provide an estimate of the mean and STD, as 
defined in Equation 1.2. 
1 T ~ = - fx(t)dt 
To 
cr = 11~ fx2(t)dt-~2 
VTo 
Equation l.1: Mathematical definition of the mean and standard deviation for signal, x, over period, T. 
- 1 N 
X=-Lx(n) 
N T1=! 
1 N cr=-VN~x2(n) ~2 
Equation 1.2: Mathematical definition of the sample mean and sample standard deviation for signal, x, 
with total number of samples, N. 
It has been noted that the sample mean and sample STD are sensitive to outlying 
samples since the entire sample set is used in their computation. An outlying sample is 
defined as a sample that differs significantly from the entire population, possibly due to 
measurement enor. Including an outlier in the computation greatly affects the estimate 
of the mean and standard deviation. Therefore, it is suggested to estimate the mean and 
STD using the sample median and inter-quatiile range. The median is defined as the 
50% percentile of the sample set, and the inter-quartile range is defined as the difference 
between the 75% and 25% percentiles of the sample set, per Equation 1.3. Note that 
since the median and inter-quartile range both employ a sorting function, the outlying 
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samples are shifted above and below the upper and lower quatiiles, respectively, and so, 
have little effect on the estimate of the mean and STD. [34] 
x = S(x(I(O.SN))) 
(J = S(x(I(0.7SN)))- S(x(I(0.2SN))) 
Equation 1.3: Mathematical definition of the sample median and inter-quaJiile range. N defines the total 
number of samples, I defines the greatest integer function, and S defines the sorting function. 
Beyond the mean and standard deviation, time based analysis also includes histogram 
analysis, derivative analysis, and non-linear analyses. Each of these analyses performs 
mathematical operations on the physiological sample set in order to highlight 
differences in the patient condition before estimating the mean and STD. 
1.6.2. Frequency-Based Analysis 
In the early 1800s, while researching the effects of heat transfer, Fourier published a 
method to analyse a signal's frequency composition. In patiicular, if a signal meets 
certain criteria, he proved that the signal may be expressed as a sum of sine waves of 
various amplitudes and frequencies, per Equation 1.4, which is telmed the Fourier 
Series (FS). 
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• X must be periodic: x(t) = x(t + T), where T is the signal period. 
• X has a finite number of discontinuities in a period. 
• X has a finite number of maxima and minima in a period. 
• X may be integrated over a period Olx(t)ldt < 00). 
0) 
If all these conditions hold, then x(t) = I (an cos(nffio t) + bn sin(nffiot)). 
n=O 
Equation 1.4: Conditions for the existence of the Fourier series. 
Equation 1.5 displays a more generalised f011n of FS using the exponential sinusoidal 
equivalence. The Fourier coefficient, cn, is determined according to the second part of 
Equation l.5. Note that the Fourier coefficient depends solely on the signal period and 
frequency, fo, since the time is integrated out. 
0) y, 
x(t) = "" c ej2mlfot ~ n where c = 1.. fx(t) e -j2rrnf"t dt , n T 
n=-CIJ 
-;I, 
Equation 1.5: Generalised Fourier series. 
Frequency analysis of a signal involves computation of the Fourier coefficient for 
various frequencies. In particular, the signal period is taken to approach infinity, per the 
first line of Equation 1.6. The period of a signal is defined as the amount of time for one 
cycle, and frequency of a signal is defined as the number of cycles per second. 
Therefore, the period is the inverse of the signal frequency, per the second equation of 
Equation 1.6, which is then substituted into the third line. As the frequency limit 
approaches infinity, the integral is defined, per the last line of Equation 1.6. This line 
also defines the Fourier transform (FT), which computes the signal's magnitude as a 
function of frequency instead of time. 
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OJ 
l. x(t) = lim ~ " X(nf ) ei2nnf"t 
T->OJ T ~ 0 
n=-U) 
2. Let L'lf = h 
en 
3. x(t) = lim L X(nfo) ei2nnfotL'lf 
M->en 
11=-00 
en en 
4. x(t) = fX(f) e i2nft df X(f)= fx(t)e-i2nftdt 
Equation 1.6: Derivation of the Fourier Transform. 
The FT is then used to analyse a set of sample measurements by determining the most 
influential frequencies; specifically, which frequencies, f, have the greatest magnitude, 
JX(f ~. Once the FT is computed for a set of frequencies, the mean of the signal 
magnitude at various frequency ranges, or spectrum, is computed in order to 
characterise the signal for classification. 
The time interval of the physiological measurement relates to the lowest resolvable 
frequency. Since the period (time interval) is inversely related to the frequency, the 
smallest measurable frequency is the maximum time interval. For example, if it is 
desired to analyse 0.05 Hz in a signal, then at least a 20-second (1/0.05) measurement of 
the physiological signal is required. Similarly, higher frequencies require less 
measurement time. 
The highest resolvable frequency of the FT is defined by the sampling rate of the signal. 
With use of computers and DAQ systems, most physiological signals are sampled at a 
patiicular rate. This rate defines the maximum resolvable frequency and is termed the 
Nyquist frequency. Specifically, Nyquist sampling theorem states that the largest 
frequency component of a measured signal must be at most half of the sampling 
frequency. 
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This may be easily shown by considering the chart in Figure 1.4. Given the original 
spectrum of the physiological signal, sampling has the effect of duplicating the 
spectrum about multiples of the sampling frequency. If the original spectrum of the 
physiological signal is greater than half of the sampling frequency, then upper 
frequencies of the physiological signal overlap, which is tem1ed, aliasing. Aliasing 
appears as distortions in the signal after sampling, and so, must be avoided by a proper 
choice of the sampling frequency. In practice, the sampling frequency is set to a 
minimum of 2.5 times the largest frequency of interest in the physiological signal. For 
example, if the HRV physiological signal has frequency bandwidth less than 2 Hz, then 
the signal may be sampled at 2.5 times 2 Hz, or 5 Hz. 
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Nyquist Rate 
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Fs Frequency 
Figure 1.4: Pictorial explanation of Nyquist sampling theorem and the minimum allowable sampling 
frequency. 
Use of the FT in signal analysis is common and often applied without considering the 
signal's parameters. Specifically, it is important to note that the conditions of existence 
for the FT are the same as the FS. Also, it is impOliant to note that since time is 
integrated out, the time of events occurring in the signal is lost. Thus, if the signal is 
non-stationaty, in other words, changes over time, the time information concerning 
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these events is lost. For example, consider stationary signal, X, and non-stationary 
signal, Y, of Figure 1.5. Both signals consist of three sine waves with different 
frequencies, 100 Hz, 200 Hz, and 300 Hz. Both signals are observable different, as one 
signal is the addition of three sine waves and the other consists of one sine wave for a 
time, a second sine wave for a time, and lastly, the third. The FT of both of these signals 
is displayed in Figure 1.6. Note that although both signals are observably different in 
time, the FT of each is essentially the same. This is due to the time-invariant 
requirements of the FT. Since time is integrated out, the FT only displays peaks at the 
three main frequencies of interests, whether or not the three frequencies are summed 
together or occur in separate time intervals. 
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Figure 1.5: Stationary signal, Y, and non-stationary signal, X, respectively. 
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Figure 1.6: Similar Fourier transforms of signals Y and X, respectively. The y-axes display the 
normalised magnitude. 
In regards to physiological signals, most are considered time varying. In other words, 
the signal changes in shape, amplitude, and spectrum over time. At one time, certain 
frequencies of a signal peak, and at a later time, other frequencies of a signal dominate. 
For example, the surface electrical activity of the brain (EEG) is known to have a 
different frequency spectrum depending on whether the subject is awake or asleep. 
Therefore, if the FT is taken of the EEG over an entire day, the time of the awake and 
asleep period spectral differences is lost. 
Even so, physiological signals are often considered to be 'wide-sense' time-invariant. 
That is to say, the signal is assumed to not change much over a certain time interval. In 
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relation to the previous EEG example, the signal may be considered time-invariant over 
shot1 time periods, over which the patient's condition is known to change little. 
1.6.3. Time-Frequency Analysis: Short Term Fourier Transform 
In order to determine time of changes in the physiological signal spectmm, time-
frequency analysis is perfom1ed. The short-term Fourier transfol1n (STFT) corrects the 
loss of time indexing of FT by segmenting the signal into regular time intervals before 
computing the FT of each. Considering the previous example of stationary signal, X, 
and non-stationary signal, Y, of Figure 1.5. The STFT was computed for each of these 
signals and displayed in Figure l.7. Specifically, the example signals were divided into 
three time intervals, 0-0.03 seconds, 0.03-0.06 seconds, and 0.06-0.09 seconds. The FT 
was then computed for each interval and normalised. Note that each example signal has 
a very different STFT with both the time and frequency information being preserved. 
Therefore, if the physiological signal requires information conceming the time of the 
spectral events, STFT analysis is appropriate. [35] 
However, STFT analysis is deficient in being able to resolve both the time and 
frequency infol111ation. Recall that the FT requires longer time intervals in order to 
resolve lower frequencies. Thus, the minimum possible time interval, llt, is set by the 
lowest frequency of interest. Specifically, the time and frequency resolution is govemed 
by the Heisenberg inequality, per Equation l.7. In other words, the more precise the 
frequency analysis, the worse the time resolution is. And, the better the time resolution, 
the worse the frequency resolution is. This deficiency in the STFT has led to 
multidimensional signal analysis, whereby the resolution of the time and frequency are 
variable depending upon the range of the time and frequency measurements. 
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Figure 1.7: The short-term Fourier transform of signals Y and X, respectively, over the time intervals, 
0-0.03 seconds, 0.03-0.06 seconds, and 0.06-0.09 seconds. The z-axes display the normalised magnitude. 
1 (~fX~t)~-
4n 
Equation 1.7: Heisenberg inequality as it relates to the STFT time and frequency resolution. 
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1.6.4. Time-Frequency Analysis: Wavelet Transform 
Similar to the STFT, the wavelet transform (WT) provides the decomposition of a signal 
over time and frequency. However, instead of decomposing the signal over sine waves, 
as is done with the STFT, the decomposition is carried out over another function, 
tenned the 'mother wavelet,' as shown in Equation 1.8. The Heisenberg inequality for 
time and frequency resolution still applies to the mother wavelet, as it did to the STFT; 
however, the mother wavelet is then scaled and shifted in time in order to provide 
multiple time and frequency resolutions, which is also shown in Equation 1.8. 
fEe(iH) if ff2<UJ 
91 
f = L:>A tpA 
A 
'" 
Wl(x) = f(x) * tps (x) = + ff(t)tp(x;t)cIt 
tp= Mother Wavelet 
s = Scale Factor (s = 2 i, where I is an integer) 
Equation 1.8: The wavelet transform and existence conditions. 
The mother wavelet scaling (changes in the frequency resolution) and dilating (changes 
in the time resolution) are carried out in powers of two with low frequencies having 
longer time intervals than higher frequencies. This gives the WT a major advantage over 
the STFT by enabling multiple resolutions, as is shown in Figure 1.8. 
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Figure 1.8: Relative STFT and WT time and frequency resolutions. 
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The choice of the mother wavelet depends upon the signal being analysed. In particular, 
the mother wavelet is chosen to match, and thus, highlight the areas of interest in the 
signal. If the signal to be analysed is sampled, then the discrete wavelet transform 
CDWT) is used to perfol1n the decomposition. For example, Figure 1.9 illustrates a 
sample DWT decomposition using a Haar mother wavelet. [36] The Haar mother 
wavelet is defined as lover half the time interval and -lover the remainder of the time 
interval, per Figure 1.9. 
Similar to FT and FS, the decomposed signal may be reconstructed. In regards to Figure 
1.9 the original function, fo, is recoverable as the sum off2, 81, and 82. The function, f2, 
is termed the 'approximation' and contains the lowest frequency infOlTIlation of the 
original signal, fo. The 8j signals are termed the 'details' and contain various frequency 
ranges of the original signal, fo. Note that throughout the decomposition, the time 
infOlTIlation has been preserved. 
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Figure 1.9: Sample DWT decomposition using a Haar wavelet. 
The WT is applied to the previous example stationary signal, X, and non-stationary 
signal, Y, of Figure 1.5. Recall that each signal consists of the same three frequencies, 
100 Hz, 200 Hz, and 300 Hz, but are noticeably different with signal Y consisting of the 
sum of the three frequencies and signal X being a single sine wave which has a different 
frequency over each time period, 0-0.03 seconds, 0.03-0.06 seconds, and 0.06-0.09 
seconds. The Haar wavelet is employed and the WT decomposition for each signal is 
displayed in Figure 1.10. Specifically, the time, approximation and detail coefficients 
for the first six levels are displayed. In order to better display the signal power, the 
absolute value is taken of each coefficient. Also, note that the detail level correlates to 
frequency ranges, with the lowest detail corresponding to the greatest frequency range. 
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Figure 1.1 0: Wavelet transform of example signals, Y and X, respectively. The z-axes display the 
absolute wavelet detail coefficients. 
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Visual inspection of Figure 1.10 displays a marked difference between the two chatis. 
The time-invariant signal, Y, exhibits a similar frequency structure over the entire time 
interval while the time-varying signal, X, displays significant changes in the frequency 
structure over each time each of the 0-0.03, 0.03-0.06, and 0.06-0.09 second time 
intervals. In patiicular, the time-varying signal, X, exhibits the lowest frequency power 
during the 0-0.03 second time interval and highest frequency power is displayed in the 
0.06-0.09 second time interval. 
According to FT identities, a periodic, sampled signal in the time domain becomes a 
periodic, sampled signal in the frequency domain. Using this fact, computer algorithms, 
termed the 'Fast Fourier TransfoID1' (FFT) have been developed to efficiently compute 
the FT coefficients. Similarly, the 'Fast Wavelet TransfoID1' (FWT) has been developed 
to efficiently compute the WT coefficients. With computational efficiency and better 
resolution, the WT is rapidly replacing the STFT for analysis of time-varying signal. 
1.6.5. Euclidian Classification Techniques 
Once a physiological signal has been analysed, the resulting features are used as a basis 
for classification. Classical classification methods involve computation of the Euclidian 
distance, as shown in Equation 1.9. The signal characterisation, X, may be 
multidimensional, and is assigned the class, C, to which X is closest to the class 
centre, c. 
I D= t(x; -c;}' 
Equation 1.9: Multidimensional distance formula between arrays X and class centre, c. 
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For example, it is desired to classify an unknown patient condition to one of four known 
conditions, as shown in Figure 1.11. This is accomplished by computing the Euclidian 
distance between the unknown condition and each of the four known patient conditions. 
The unknown condition is assigned to the condition which gives the minimum distance. 
This type of classification is tem1ed a nearest-neighbour classifier and is implemented in 
Figure 1.12 by a MatLab m-file. 
Figure l.l1: Euclidian classification example. The unknown patient condition is classified as condition 2 
based upon the closest distance. 
Function [class]=class4data(data, c1, c2, c3, c4) 
% CLASS4DATA Given an matrix of data, this function classifies the data 
% 
% 
according to the class centres, cl, c2, c3 and c4, using 
the nearest neighbour criteria. 
% 
% The data is organized into a matrix of column data sets and 
% row features. A 1 indicates classification to class 1, 2 indicates class 2, 
class=[]; Ld = size(data); 
for i=1:Ld(2) 
tl = sum((cl - data(:,i)).A2).AO.5; t2 
t3 = sum((c3 - data(:,i)).A2).AO.5; t4 
if (tl < t2) & (tl < t3) & (tl < t4) 
class [class 1]; 
else 
if (t2 < tl) & (t2 < t3) & (tl < t4) 
class [class 2]; 
else 
if (t3 < tl) & (t3 < t2) & (t3 < t4) 
class = [class 3]; 
else 
class 
end; 
end; 
end; 
end; 
[class 4]; 
sum((c2 - data(:,i)).A2).AO.5; 
sum((c4 - data(:,i)).A2).AO.5; 
Figure 1.12: Classification based upon the minimum Euclidian distance to the class centre. 
44 
Besides mImmum distance, Euclidian classification may consider the probabilistic 
distribution of the known patient conditions. This type of classification is known as 
Baysian classification, which provides a significant improvement in classification 
perfOlmance. Specifically, the condition decision is based upon discriminating 
functions, which are used to determine the classification, as shown in Figure 1.13. 
Classification 
Figure 1.13: Classification into one of N conditions according to discriminating function, gj. 
The discriminating functions may be detelmined by either supervised or unsupervised 
learning. [37] Supervised learning has the advantage of training the classifier with 
known patient conditions and the associated probabilistic distributions. Unsupervised 
learning does not require a priori knowledge of the patient conditions and can even 
estimate the number of different patient conditions within a data set; however, this is 
often set as an input to the algorithm. 
Figure 1.14 displays an algorithm flowchmi that uses unsupervised learning and 
Euclidian minimum distance in order to detennine N class centres. Specifically, the 
algorithm initialises by assigning the first N samples of the data to the N cluster centres, 
respectively. Then, these cluster centres are used as a basis for classification by 
assigning each sample to the nearest class centre. Once all the samples have been 
assigned to one of N classes, a new class centre is computed from the assigned class 
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members. Tennination occurs when the new class centres do not change by 8 from the 
previous class centres. 
...-----.... 
START 
-. 
N '" Number of classes 
M '" Number of samples 
C(\ .. N) '" Class centres 
LastC( I..N) '" Previous class centres 
C(I..N) = LastC(I..N) = Sample(1..N) 
... 
·1 For i = I to M : 
... 
I For j = I to N I 
• I Compute Euclidean distance from Sample, to each class centre, Cj . I 
.. 
I Nextj I I 
.. 
I Assign Sample, to class with minimum Euclidean distance. J 
t 
I Nexti I I 
... 
I Compute class centres, C(\ .N) I 
.. 
I 
Compute Euclidean distance between class centres, C(I .. N), and previous I 
class centres, LastC(I .. N). Determine the maximum distance, D. 
NO G0 0>8 
YES 
I LastC(I .N) = C(I..N) I I 
Figure 1.14: Flowchati of the unsupervised learning algorithm for N clusters. 
Figure 1.15 displays a MatLab m-file implementation of the flowchart in Figure 1.14 for 
computing four class centres using unsupervised learning. As with the flowchart, the 
algorithm begins by assigning the class centres to the first four samples. Then the entire 
sample set is classified using the minimum distance, or nearest neighbour, criteria. That 
is, each sample is assigned to the class which gives a minimum distance to that class's 
centre. Once all the entire data set has been classified, the class centres are re-computed 
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as the sample mean of all the class members. Then, using the new centres, the entire 
sample set is again classified, and the class centres are again computed. The algorithm 
terminates when the Euclidian distance between the old class centres and the new class 
centres is less than a given value, O. For robustness and to avoid oscillatory conditions, a 
maximum of 1000 iterations is allowed for the algorithm. 
Supervised leaming incorporates knowledge about the patient condition. Specifically, if 
the observations of the known patient conditions are normally distributed, then the 
observation mean and STD may be used to describe the class centre and distribution. 
Fmihermore, the class may be described with more than one dimension. In other words, 
the class centre is a vector of values with each being the sample mean of that patiicular 
dimension, as shown in Equation 1.10. Similarly, the multidimensional class 
distribution is described by the covariance matrix, as shown in Equation 1.11. [38] 
1 N 
c (CI'C 2 ,,,,C M ) where,c i =-IXij N j=I 
Equation 1.10: Class centre, c, with dimension, M, is determined from N observations, x. 
2 0' II 2 O' Ij 
2 
O' IM 
L: = -1-10';1 2 2 
1 N 
O' ij O' iM where, 0' .. = - I(x. - c· )(x. -c.) N -1 . IJ N I I J J j=I 
2 
O' MI 
2 
O' Mj 
2 
O' MM 
Equation 1.11: Class covariance, I, with dimension, M by M, is determined from N observations, x, and 
class centre, c. 
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Function [c1, c2, c3, c4, iter]=nfourc1ass(data, delta) 
% FOURCLASS Given a matrix of data, this function determines the centres 
% 
% 
% 
% 
% 
of four classes using unsupervised learning and nearest 
neighbor criteria. The total number of iterations used 
to find the class centres is also returned. 
The data is organized into a matrix of column sets and row features 
iter = 0; 
c1=data(:,1); lc1=c1; c2=data(:,2); lc2=c2; c3=data(:,3); lc3=c3; c4=data(:,4); lc4=c4; 
while 1 
iter = iter + 1; 
if (iter> 1000) % CHECK FOR UNSTABLE SOLUTION 
returni 
end; 
class1=[]; class2=[]; class3=[]; class4=[]; 
for i=1:1ength(data) 
t1 sum((c1 data(:,i)).A2).AO.S; t2 
t3 = sum((c3 - data(:,i)).A2).AO.S; t4 
if (t1 < t2) & (t1 < t3) & (t1 < t4) 
class1 = [class1 data(:,i)]; 
else 
if (t2 < t1) & (t2 < t3) & (tl < t4) 
class2 = [class2 data(:,i)]; 
else 
if (t3 < t1) & (t3 < t2) & (t3 < t4) 
class3 = [class3 data(:,i)]; 
else 
class4 
end; 
[class4 data(:,i)]; 
end; 
end; 
end; 
if -isempty(class1) 
Lc = size(class1); 
if Lc(2) > 1 
c1 
else 
c1 
end; 
end; 
mean(class1') '; 
class1; 
if -isempty(class2) 
Lc = size(class2); 
if Lc(2) > 1 
c2 = mean(class2')'; 
else 
c2 
end; 
end; 
class2; 
if -isempty(class3) 
Lc = size(class3); 
if Lc(2) > 1 
c3 
else 
c3 
end; 
end; 
mean (class3' ) , ; 
class3; 
if -isempty(class4) 
Lc = size(class4); 
if Lc(2) > 1 
c4 
else 
c4 
end; 
end; 
mean(class4') '; 
tl 
t3 
class4; 
sum( (c1 
sum( (c3 
lc1) .A2) .AO.S; t2 
1 c3) . A 2) . AD. S; t 4 
sum( (c2 
sum( (c4 
sum ( (c2 
sum( (c4 
data(:,i)) .A2) .AO.S; 
data(:,i)) .A2) .AO.S; 
lc2) . A 2) . AD. S; 
lc4) .A2) .AO.S; 
if (t1 < delta) & (t2 < delta) & (t3 < delta) & (t4 < delta) 
return; 
end; 
lc1 c1; lc2 c2; lc3 c3; lc4 c4; 
end; 
Figure 1.15: Mat Lab m-file algorithm to compute four cluster centres using unsupervised learning. 
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Given the multivariate class centre, c, and covariance, I, a new classifier is defined 
using the Mahalanobis distance equation, as shown in Equation 1.12. Similar to nearest-
neighbour classification, the Mahalanobis distance is computed between the unknown 
patient condition and known class centres, with consideration of the class distributions. 
The unknown patient condition is then assigned to the class with the minimum distance. 
[39] Figure 1.16 displays a MatLab m-file implementation of this classification given 
two class centres and their associated covariance matrices. 
I D ~ ~(x - c)'I;-'(x -c) 
Equation 1.12: Mahalanobis distance between sample vector, x, and class centre, c. 
Function [class)=class2data(data, c1, c2, sl, s2) 
% CLASS2DATA Given an matrix of data, this function classifies the data 
% according to the class centres, cl and c2, give the associated covariance 
% matrices, sl, and s2. 
% 
% The data is organized into a matrix of column data sets and 
% row features. A 1 indicates classification to class 1, 2 indicates class 2. 
class=[); Ld = size(data); 
for i=1:Ld(2) 
dl (data(:,i)-cl)'*inv(cl)*(data(:,i)-cl); 
d2 = (data(:,i)-c2)'*inv(c2)*(data(:,i)-c2); 
if (d1 < d2) 
class [class 1); 
else 
class [class 2); 
end; 
end; 
Figure 1.16: Classification based upon the minimum Mahalanobis distance to the class centre. 
1.6.6. Neural Network Classification Techniques 
Recent developments in the field of neural networks (NN) have provided powerful tools 
for classification. This is especially true when the problem at hand is a complex one, 
with many interdependent variables. By simulating the behaviour of a biological 
neuron, a network capable of self-leaming which of the signal features are important for 
classification. Many leaming algorithms and network topologies have been developed. 
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It has also been shown that depending on the nature of the problem at hand, different 
network topologies perf 01111 differently. [40] [41] 
For this study, the network training is carried out on a commercially available aIiificial 
neural network package, NeuroShe1l2 that is displayed in Figure 1.17. The package 
builds, trains, and applies Group Method of Data Handling (GMDH) polynomial 
networks. These networks are implemented using polynomial functions to model the 
functioning of individual neurons, as per the work of Prof. A. G. Ivakhnenko from the 
Institute of Cybe111etics, Ukrainian Academy of Sciences. [42] 
f£~ 
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.J 
j----' -
IYoll may type a description of yow plOblem for later reference. 
Figure l.l7: Commercial neural network design and training package, NeuroShe1l2. 
The exact number of neurons and layers in the NN are determined by trial and 
observation. Once a specific architecture is chosen, it is trained on the known patient 
conditions. The trained NN is then applied to additional patients with lmown conditions 
in order to test the classification. 
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Specifically, in using the NeuroShell2 package, the design process involved assigning 
the training data, building the network, and then testing the network by applying it to 
sample sets, as per Figure 1.18. Once the network has been built, the neuron weights 
and network calculations are exported and integrated with other programming packages, 
such as MatLab. The polynomial calculations tend to be many and complex. 
Furthermore, it is often not clear upon what the NN is basing its classification. Even so, 
it has been shown that a NN is able to perform superior to that of classical classification. 
[43] 
1m -=:lc!.IB 
Problem Build Apply Problem 
Input Neural Neural Output 
Network Network ~ BJJ kt··W :a: ... O!:'..1)ii ... ... c:J 
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File Export 
Inputs / File 
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Test Set Output 
Extract File 
m 
Learning 
I~fanually enter data here for your problem 
Figure 1.18: NeuroShell2 application for building and training neural networks. 
1.6.7. Classification Assessment 
Once a classification system has been designed, it is assessed to detem1ine its ability to 
screen a patient for disease. In this study, the patient is screened for both DM and CHD. 
In medical practice, the effectiveness of a clinical screening is detelwined by computed 
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the sensitivity, specificity, positive predictive value, and negative predictive value 
statistics, according to Equation 1.13. [44] The sensitivity is the probability that a 
diseased patient is conectly classified as having the disease. The specificity is the 
probability that a normal patient is conectly classified as not having the disease. The 
positive predictive value is the probability that a person has the disease given a positive 
classification result, and the negative predictive value is the probability that a person 
does not have the disease given a negative classification result. 
Classification Results 
Known Patient Condition Negative Positive 
Disease Absent A B 
Disease Present C D 
S ... d S 'fi' a ensltIvlty = -- pecl lClty = --
c+d a+b 
P .. P 'd' . V 1 d Negative Precidictive Value =_a_ oSltIve reCl lctIve a ue = --
b+d a+c 
Equation l.l3: Evaluating classification results by determining the sensitivity, specificity, positive 
predictive value and negative predictive value. 
For example, a certain classifier is used to screen 10,000 patients for DM. 9,620 of the 
patients are known to be non-diabetic and 380 are known to have DM. The results of the 
classification are displayed in Figure 1.19. According to the results, the classifier has a 
sensitivity of 0.895, which is means that 89.5% of the time, the classifier correctly 
detects a patient with DM. The specificity is 0.90, which means that 90% of the time, 
the classifier conectly assigns a non-diabetic patient as free of DM. The negative 
predictive value is 0.995, which means that if the classifier indicates the patient is free 
of DM, then 99.5% of the time, the classifier is correct. The positive predictive value is 
0.26, which means that if the classifier indicates that the patient is diabetic, then only 
26% of time is the patient truly diabetic (a false positive). In other words, this example 
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classifier is good for screening patients for DM, but if it indicates a patient is positive 
for DM, then fmiher testing is required in order to ensure the patient truly has DM. [45] 
Classification Results 
Known Patient Condition Negative for DM Positive for DM 
DM Absent 8660 960 
OM Present 40 340 
. . . 340 0.895 S . fi . a 8660 0 90 SensItIvIty = pecI IClty = -- = = . 
40+340 a+b 8660+960 
+ Precidictive Value = 340 = 0.26 - Precidictive Value = 8660 = 0.995 
960+340 8660+40 
Figure 1.19: Example assessment of a DM classifier. 
1.7. Heart Rate Variability 
The HR is controlled by the sympathetic and parasympathetic branches of the 
autonomic nervous system (ANS). The parasympathetic nerves (Vagus) slow the HR 
through the release of acetylcholine. Sympathetic nerves accelerate the HR through the 
release of noradrenaline. The variability of the HR is the result of a balance between the 
sympathetic and parasympathetic nerves. These two branches of the ANS serve as a 
control system for the HR in order to respond to changing conditions of the cardiac 
load. [46] 
The diagram in Figure 1.20 describes the basic circulatory system. The circulation and 
arterial blood pressure are affected by the cardiac output, specifically, the HR and stroke 
volume. The hemi itself is control by the central nervous system, specifically, the ANS. 
Baroreceptors are sensors that detect pressure in the aortic arch and carotid arteries. 
These sensors serve as feedback for the HR control system. Additionally, 
chemoreceptors are sensors used to measure chemical variables, such as the pH sensors 
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in the medulla, which in tum, also provides control of the respiration and HR through 
the release of adrenaline by the adrenal medulla. 
Autonomic Nervous System 
Chemoreceptors 
Heart 
Baroreceptors 
Circulation 
Figure 1.20: Basic circulatory system block diagram 
Sinus Node 
Heart Rate 
Stroke Volume 
Fluctuations in HR (and thus the ABP) are quasi-periodical, repeating with a period, 
which are not strictly constant, showing changes in morphology, amplitude and phase 
from one beat to the next. In steady state conditions, these oscillations are maintained 
around a celiain mean value. For the human, with no ANS control, the heart beat is 
approximately 100 beats per minute (BPM). With ANS control and resting, the 
parasympathetic response dominates and the HR lowers to approximately 70 BPM. 
During exercise, the sympathetic response dominates and the HR increases accordingly. 
The beat-to-beat variation in HR is the HRV, which may be easily monitored non-
invasively in a clinical setting. Since the HR is controlled primarily by the ANS, 
measurement of the HRV provides infoll11ation about the sympathetic and 
parasympathetic cardiovascular control mechanisms. [47] However, the HRV is also 
affected by respiration, mental stress, cardiovascular disease, dlUgs, ectopic beats and 
age. 
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In case of dysfunction, compensatory changes occur in order to keep the entire 
circulatory system withinnom1al operating limits. [48] Specifically, reduced HRV may 
indicate the presence of DAN and that the sympathetic and parasympathetic nervous 
systems are not coordinating an appropriate HR response. Additionally, it has been 
shown that the HRV spectrum is affected by the presence ofCHD and CVD. [49] 
1.7.1. Time-Based Analysis of HRV 
Analysis of the HRV has usually focused on the standard deviation of normal-to-normal 
(SDNN) beats in the ECG. Specifically, the STD of time between consecutive normal 
R-waves is computed. Since the STD computes a measure of the data range, the STD of 
the time intervals gives a measure of the HRV. 
Traditionally, the HRV was measured over a 24-hour period. Specifically, the STD of 
5 minute intervals (SDANN) were computed and then averaged. However, 24-hour 
measurements are not easy in a clinical setting. Therefore, in this study only short-term 
(30-minute) HRV analysis is used. [50] 
Besides the STD, the root-mean-square of the difference between successive RR 
intervals (rMSSD) is used as an estimate of the HRV derivative. Similarly, with the 
trend removed, the number of zero crossings (ZC) serves as an indicator of highest 
frequency component within the HRV. Each of these analyses is discussed in detail in 
Chapter 4, HRV Analysis. 
1.7.2. Frequency-Based Analysis ofHRV 
Since the early seventies, modem signal analysis techniques have been applied to the 
HRV and ABP. Helped by recent developments in computer hardware and software, 
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power spectral analysis (PSA) of cardiovascular signals assumed a prominent place as a 
simple, non-invasive tool in the armoury of cardiovascular system tests. Regrettably, the 
introduction of this test into clinical medicine has been slow, because the PSA is a 
difficult concept for many physicians. Moreover, a thorough comparison between PSA 
and classic diagnostic methods is not yet available. Also, diabetics have been 
unfortunately excluded from all studies investigating HRV and PSA in CHD. Obviously 
the cause is the complexities that arise in design, methodologies and analysis by 
compounding the effect of age, DAN and DM. 
The power spectrum (PS) of the HRV consists of three major frequency bands ranging 
from 0 to 0.5 Hz. The boundaries of these bands are not strictly defined. The most 
commonly accepted bands are the very low frequency (VLF) band from 0.02-0.05 Hz, 
the low frequency (LF) band from 0.05-0.15 Hz, and the high frequency (HF) band 
from 0.15-0.5 Hz. Changes in each of these bands conespond to specific physiological 
changes. 
Variations in the VLF band relate to temperature regulation of the body, the vasomotor 
control and the renin-angiotensin system, with a centre-of-frequency at 0.04 Hz. The 
rennin-angiotensin system refers to the hOl1none rennin which is released by the kidneys 
to catalyze the production of angiotensin and secretion of aldosterone, which regulates 
blood volume, and in tum, ABP and HR. An ultra low frequency band (ULF) from 
0.01-0.04 Hz has also been described for long-tenn studies, but its exact physiological 
significance is not readily apparent and is not used for short-term HRV studies. 
Variations in the LF band relate to the ABP control system. It has a centre-of-frequency 
at about 0.1 Hz and is called the Mayer band, corresponding to oscillations in blood 
pressure described by Mayer in 1874. It is influenced by parasympathetic and 
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sympathetic systems with an increase in vagal activity causing a spectral peak in this 
frequency range. Conversely parasympathetic blockade diminishes LF power, especially 
in the supine position. 
Interventions that increase sympathetic activity include passive tilting, standing, mental 
and physical stress, sympathomimetic agents, baroreceptor unloading with 
nitroglycerine infusion and coronary occlusion. Thus, these are also known to increase 
the power in the LF band. However, the magnitude of the power in this band decreases 
monotonically with age. Breathing does not influence it, when the respiratory rate is 
above 9 BPM. In supine position, its magnitude is mainly dependent on parasympathetic 
system. 
Variations in the HF band relate to respiration and are associated with parasympathetic 
activity with a centre-of-frequency at 0.25Hz, which varies with the respiratory rate. 
This band is mediated solely by the parasympathetic system. The magnitude of the 
power in this band is more in the supine than the standing position. There is a linear 
decline in the power of this band up to the age of 30 years, and does not change 
thereafter. [51] 
1.7.3. HRV and Power Spectral Analysis Changes in Disease 
Normal individuals show a progressive decrease of HRV with age with a loss of 4.6 
beats per each decade of life. However, almost two-thirds of patients with clinically 
detectable peripheral neuropathy, such as buming feet, decreased knee and ankle 
reflexes, decreased pinprick, position and vibration sense, have significant changes in 
HRV. Furthermore, all patients with clinically detectable DAN have abnormal HRV. 
[52] 
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Additionally, CHD causes a reduction of HRV and a shifting of the LF and HF 
components. The reduction correlates well with the angiographic severity but not with 
other CHD features, including the presence of a previous myocardial infarction, location 
of diseased coronary arteries, and indices of left ventricular function. There is also 
reduction in the LF power which is attributed to the decrease in vagal out-flow, since 
there is no change in the LF/HF ratio, which suggests that the sympathetic cardiac 
function is not affected in CHD. 
1.7.4. Time-Frequency Based Analysis of HRV 
Although the time based and frequency based analyses are different, the results are 
comparable since SDNN is theoretically the same as the total spectral power of the 
HRY. Similarly, the rMSSD and ZC time analyses correlate well with the HF band. 
However, the HR is dynamic, changing continually over time in response to various 
conditions and cardiac loads. This means the HRV signal is not stationary and 
additional infoffilation maybe found by analysing the HRV signal in response to various 
actions such as resting, standing, and controlled breathing. In order to best characterise 
the HRV signal, new analyses techniques are required which preserve both the time and 
frequency components of the signal. Time-frequency analysis allows the HRV spectral 
bands to be computed over time as the patient performs various actions in the clinical 
setting. It is hypothesised that the normal patient response differs from the diseased 
patients providing a low-cost, efficient screening for DM and CHD. 
58 
1.8. Summary 
The world prevalence of DM is rising and projected to increase astronomically. DM is 
also a major health conce111 in the Middle East and especially in the UAE where surveys 
suggest that 20% of UAE citizens are diabetic. 
A variety of health complications are associated with DM including DAN, retinopathy 
and amputations. However, CHD and CVD complications are the most common causes 
of morbidity and mOliality in diabetic patients. In general, the severity of complications 
becomes worse as the disease progresses. Early detection of DM and CHD, combined 
with proper treatment, can delay the progression of the disease and rise of 
complications. Unfortunately, many DM and CHD patients are unaware they have the 
disease. 
In the clinical setting, measurement of non-invasive physiological signals such as ECG, 
ABP, and respiration have become possible with the rise of low-cost computers and 
physiological acquisition system. Non-invasive screening greatly reduces the risks of 
infection and increased patient stress. From the ECG, the beat-to-beat HR may be 
extracted and analysed. Variations in the HR differ between n01111al patients and those 
with DM and CHD. These differences are apparent in both time and frequency analyses. 
Therefore, non-invasive physiological signals may be used in the clinical setting to 
efficiently screen patients for DM and CHD. 
Specifically, the HRV signal may be extracted from the ECG and used as a means of 
patient screening. The HRV spectrum varies in response to specific actions such as 
resting, standing, and controlled breathing. Analysis of these HR V spectral over time 
may provide a suitable basis for classification of patients into N, DM, CHD, and CHDD 
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classes, and thus, providing a quick, low-cost, and effective means for clinical 
screemng. 
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Chapter 2 - Clinical Data Acquisition System 
2.1. Introduction 
In order to research the effectiveness ofDM and CHD clinical screening based upon the 
HRV signal, a data acquisition system to collect the patient physiological data is 
required. This chapter details the clinical DAQ system and methodology of collecting 
the patient physiological data. Specifically, the required hardware components of the 
system and the routine a clinical technician used to screen a patient are presented. 
Furthermore, the custom developed software programmes used by the technician are 
introduced and explained. 
The specific goal of the system is to record HRV physiological data as it changes over 
time in response to various patient activities. Although the HRV data is computed only 
from the ECG, the patient ABP and respiration are recorded and studied as possible 
additional indices to the patient's cardiac condition. Also, in order to detern1ine the 
classification performance, the patient's medical histOlY and laboratOlY results are 
recorded in order to assess the patient's cunent condition. 
2.2. Methodology 
The patient physiological data is collected by use of a personal computer (PC) and non-
invasive DAQ system, as displayed in Figure 2.1. Use of a PC reduces the overall cost 
of the system and allows for a simplified user interface. Non-invasive physiological 
measurement allows for the patient to be screened in a clinical setting with reduced 
patient stress and little concern of infection. 
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Figure 2.1: Clinical equipment and setting. 
As far as the screening procedure, the patient is initially connected to the physiological 
measurement equipment and requested to lie (supine) quietly on the examination table, 
as per the clinical procedure of Appendix E. Then, the patient's medical history and 
laboratory results are recorded. Specifically, the patient's name, telephone number, 
hospital number, sex, age, height, weight, hip circumference, waist circumference, and 
cigarette usage, treatment for diabetes, blood pressure, activity index, and anxiety index 
are recorded, per Appendix F. The activity and anxiety indices are detem1ined according 
to questionnaires located in Appendix A and B, respectively. This data is taken for an 
associated study which conelates anxiety and activity to disease, specifically the 
presence of DM and CHD. The laboratory results focus on various tests, which are 
detailed in Appendix C. Besides completing the medical history and determining the 
patient's activity and anxiety indices, the interaction between the patient and technician 
allow for the patient to feel at ease with the connections to the physiological 
measurement equipment. This, in tum, lowers the patient's stress and reduces the 
hypeltension artefact in the measurement of the physiological data. 
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Once it appears to the technician that the patient is at ease, 5 minutes of supine 
physiological data are collected, as per the clinical procedure of Appendix E. The 
average human hemi rate is approximately 70 beats per minute, and so 5 minutes of 
electrocardiogram acquisition collects 350 beats, which subsequently gives 350 HRV 
samples. Similarly, the average human respiration is approximately 10 breaths per 
minute, and so 5 minutes of chest pressure data gives about 50 breath samples to base 
the respiration measurement. 
The technician then requests the patient to stand and another 5 minutes of physiological 
data are immediately collected. Then, the patient is asked to sit/squat and another 5 
minutes of physiological data are collected. Lastly, the patient is requested to breathe at 
9, 12, and 15 breaths per minute, each for a 5-minute duration. During each of the 
patient controlled breathing durations, the patient's physiological data are again 
collected. In order to assist in timing their breaths, the patient is requested to breathe 
according to respiration timer programme. Therefore in summary, each patient action is 
characterised by approximately 350 cardiac beats and 50 breaths. 
2.3. Hardware Requirements 
Figure 2.2 summarises the clinical system to record the patient information. Besides the 
PC and DAQ board, three extel11al devices are used to measure the patient respiration, 
ABP, and ECG. Each device outputs a voltage signal, which is calibrated to the 
respective physiological measurement. The DAQ digitises the relative voltage signal 
and the PC implements the calibration equation to determine the physiological 
measurement. 
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Patient History and 
Laboratory Results 
Lead II ECG Pre-Amplifier 
Personal Computer 
running Lab VIEW 
Pressure Monitor 
12-bit Data Acquisition 
Respiration Custom Monitor Board 
Figure 2.2: Data acquisition system block diagram. 
The DAQ board, which is installed in the PC, is the National Instruments' [53] PCI-
6023E, l2-bit data acquisition board, as shown in Figure 2.3. The board is low-cost and 
may be configured to digitise various voltage ranges using 12 bits of resolution. For 
example, if the 0 to 10 V DC voltage range is chosen, then 0 V DC is assigned the value 0 
and 10 VDc is assigned the value 4096. Using this voltage range, the resolution is 
computed as the voltage range per total DAQ-count (10 V DC / 4096), which, for this 
voltage range, is approximately 2.4 mY. Therefore, the least count (smallest measurable 
voltage) for this voltage range is 2.4 m V. 
PCI-6023E 
• Available for PCI computers 
• Up to 16 analog inputs; 12-bit resolution; 200 k8/s sampling rate 
• 8 digital 1/0 lines (5 VffiL); two 24-bit counter timers 
• Calibration certificate included 
• I~I-DAQ driver with Measurernent and Automation Explorer for 
easy configuration 
Figure 2.3: National Instruments PCI-6023E data acquisition board with associated specifications. 
As far as sampling frequency, the National Instruments' PCI-6023E has a maximum rate 
of 200K Samples per second for a single data channel. Since the clinical system is 
collecting three channels of data (ECG, ABP and respiration), the maximum acquisition 
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rate is 200K / 3, or approximately 67K Samples per second. This limit far exceeds the 
sampling frequency requirements for ECG, ABP and respiration, and so, the DAQ 
board is acceptable for using the clinical system. 
2.3.1. Electrocardiogram Acquisition 
In order to best detect the ECG R-waves, the QRS complex of the ECG is maximised 
through placement of the patient electrodes in the Einthoven bipolar positions (Figure 
2.4). With these electrode positions, Lead II ECG is acquired as per the guidelines of the 
European Society of Cardiology and the North American Society of Pacing and 
Electrophysiology. [54] Specifically, the ECG is amplified to the voltage range and 
sampled at 500 Hz. 
Figure 2.4: Electrocardiogram Lead II electrode connections and lOOOx ECG pre-amplifier. 
The Lead II electrode positions provide an ECG signal in the range of a few milli-Volts 
(mV). [55] In order to amplify the ECG signal for the DAQ, a battery-operated, lOOOx 
pre-amplifier is employed. A gain of 1000x magnifies the m V ECG signal into the Volts 
range. Operating the pre-amplifier on battelY power eliminates the need for an 
expensIve and complex AC to DC power conversion circuit. All AC to DC power 
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conversion circuits leak AC ripple-voltage, which is usually in the m V range. However, 
since the ECG measurement is also in this range, it is common for the AC ripple-voltage 
to COlTUpt the ECG signal. This is especially a problem since the AC power operates at 
50 Hz, which is in the midst of the known ECG spectrum. Utilising battelY power for 
the pre-amplifier eliminates this concem of the AC ripple-voltage. Since the pre-
amplifier draws little power, a single 9 Voc transistor battery provides more than 24 
hours of operation. 
Figure 2.5 summarises the ECG pre-amplifier circuit through use of a block diagram. 
The initial isolation-buffer amplifier provides high input impedance that is greater than 
10 MO. The second stage, differential amplifier allows for enhanced common mode 
rejection, which reduces interference common to both the right am1 and left arm 
electrodes. The third stage is a 50 Hz low pass filter, which is used to suppress induced 
power-line noise. The final stage amplifier provides signal gain, which is adjusted to 
provide an overall amplification of 1000x. 
Right 
Arm 1-+ Isolation Differential 50Hz Amplifier 
Buffer ~ Amplifier ~ Low ~ 
Left f-+ Amplifier Pass 
Arm ! 
Output 
Right Leg Left 
Leg ~ Driver Amplifier 
Figure 2.5: Electrocardiogram lOOOx pre-amplifier block diagram. 
The details of the ECG pre-amplifier circuit are displayed in Figure 2.6. The circuit 
operates on a single 9 Voc battery and utilities LM358 operational amplifiers operating 
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on single-ended voltage rails (0 Voc and 9 Voc). The ECG baseline is adjusted between 
the rails (~4.5 Voc), which allows for a 4.5 Vocmaximum deflection. 
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The pre-amplifier output signal is sampled (Fs) by the DAQ at a rate of 500 Hz, as per 
the guidelines of the European Society of Cardiology for detem1ine HRV from ECG. 
[56] Therefore, the detection time of the ECG R-wave has a resolution of 11500, or 
2 ms, as shown in Equation 2.1. 
ECG Voltage = DAQ Count --( { IOmV) 4096 
( IOmV) Least Count = -- ~ 2.4)..1 V 4096 
Resolution = ( 1 ) 2ms 
500Hz 
Equation 2.1: ECG DAQ calibration equation, least count, and time resolution calculations. 
The DAQ board is configured to digitise the 0 to 10 Voc range. Therefore, the 
calibration of Equation 2.1 is used to detem1ine the ECG physiological measurement of 
a given DAQ count. Note the units are in mY, considering the 1000x effect of the ECG 
pre-amplifier. Also displayed in Equation 2.1 is the least count of the ECG 
measurement. The least count defines the smallest resolvable voltage of the ECG. 
2.3.2. Arterial Blood Pressure Acquisition 
The patient's ABP is acquired using an Ohmeda Finapres 2300 [57] and finger cuff, as 
pictured in Figure 2.7 and Figure 2.8, respectively. The device uses the 
plethysmography of the index finger as a means to indirectly measure the ABP. 
Plethysmography is defined as measurements in the variation of the size of an organ or 
body part, based on the amount of blood passing through it. The Ohmeda clinical device 
inflates a cuff around the index finger and thus restricts the blood flow in the finger. It 
then releases the pressure in the cuff until variations in the pressure due to the ABP are 
detected. These variations are then automatically calibrated to the ABP by the device. In 
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order to ensure accurate measurements, the Ohmeda device automatically self-calibrates 
the ABP against the plethysmography variation of the index finger once evelY minute. 
Figure 2.7: Ohmeda Finapres arterial blood pressure monitor. 
Figure 2.8: Ohmeda Finapres finger transducer. 
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Besides measuring the ABP, the Ohmeda Finapres monitor provides an output port that 
generates 1 VDC for every 100 mmHg of ABP. A human has a positive ABP, which is 
normally less than 500 mmHg. Therefore, the DAQ board is configured to digitise the 
Ohmeda Finapres output voltage in the 0 to 5 VDC range. The sample frequency is set to 
500 Hz in order conespond with the ECG acquisition. Given these settings, the ABP 
DAQ calibration and least count are displayed in Equation 2.2. Note the ABP units are 
inmmHg. 
ABP Pressure = (DAQ Count" 5Voc )(IOOmmHg] Jl 4096 IV oc 
Least Count = ~ == 0.12mmHg ( 5V )( 100mmHg] 4096 IVoc 
Resolution ( I ) = 2ms 
500Hz 
Equation 2.2: ABP DAQ calibration equation, least count, and time resolution calculations. 
~ 
Figure 2.9: Respiration monitor and placement of pressure transducer. 
2.3.3. Respiration Acquisition 
The patient respiration is acquired by using a custom built clinical device [58] that 
outputs a voltage conesponding to changes in a pressure transducer strapped to the 
71 
patient's diaphragm, as shown in Figure 2.9. Specifically, an elastic band is strapped 
around the patient and a pressure transducer is placed in the mid-chest region. As the 
patient inhales, the patient's lungs expand and cause an increase in pressure upon the 
transducer. Similarly, as the patient exhales, the lungs reduce in size and the transducer 
experiences a reduced pressure. The device reads the differences in pressure and outputs 
a corresponding voltage in the range of 0 to 5 V. Since the time between the pressure 
peaks are used to determine the rate of respiration, the output voltage is not calibrated to 
the actual pressure. The output voltage is over-sampled at 500 Hz in order to use the 
same data structure as the ECG and ABP and ease computer storage of the infOlmation. 
Once acquired, the respiration is determined as the sampling period multiplied by 
number of samples between two consecutive chest pressure peaks, as per Equation 2.3. 
Note that Pi is the sample-number a detected peak in the chest pressure wavefom1, and 
so, (Pi - Pi-I) is the number of samples between two pressure peaks which corresponds to 
one full breath-cycle. The units ofrespiration are breaths per minute. 
R .. [ I Breath ](500 samPles)(60sec) esplratlOn = --. -
(Pi - Pi-I) sec n11n 
Equation 2.3: Computation of patient respiration. 
2.4. Software Requirements 
The software developed for the study is classified into two categories: DAQ and 
utilities. All programmes were developed using the Lab VIEW application development 
package and consist of the Patient Data Collection, Patient Data Review, Patient 
LaboratOlY Editor, and Patient Data Extraction programmes. 
72 
2.4.1. National Instruments' LabVIEW 
LabVIEW is an acronym for Laboratory Virtual Instrument Engineering Workbench. 
This application development package features a graphical programming environment 
with tools necessary for DAQ, data analysis, and graphical presentation. Recent years 
has seen an increasing use of Lab VIEW in both industry and scientific research. This is 
largely due to the ease of writing complicated applications without the requirement of 
compilers and rigid English-based code. 
LabVIEW programmes are called Viliual Instruments (VIs) because the user interface 
resembles an instrument with buttons, switches, and graphical output. A VI consists of a 
front panel and a block diagram. The front panel specifies the inputs and outputs of user 
interface. It consists of digital controls for user input and digital indicators for output 
display, as shown in the example programme of Figure 2.10. The block diagram 
consists of icons, which represent input, output, operations, structures, and subroutines. 
The block diagram contains the VI programming instructions. The programme is 
defined through wiring connections between the controls, indicators, and icons, which 
represent mathematical functions, constants, and programme control structures, as 
shown in the example VI of Figure 2.12. 
Run I~=~~I~ T::i~-~r==,~i I ,--=-,,--.,---,..-:-;----r 
Digital 
Control 
Time in hours 
," d 16.00 
'.' 
VeloCity in Kph 
/' ~} 750.00 
Distance in Km Align Objects 
1rOO ,00 
Digital Indicator 
Figure 2.lO: Front panel of an example Lab VIEW programme to compute distance. 
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... 
13> 
Distance in Km I 
'~ Output 
\ 
ITimei~ hoursl 
Inputs '." 
WelocitY in Kphl 
.~ Wire Connections 
.... 
Figure 2.11: Block diagram of an example Lab VIEW programme to compute distance. 
Lab VIEW departs from traditional English-based coding. The coding is termed 'G' for 
graphical-based coding and requires a new way of thinking about programme 
construction. Instead of writing lines of code and calling subroutines, a VI employs 
wires connecting icons together. The icons may represent operations such as 
multiplication, programme flow structures, such as loops, or subroutines. The wires 
represent the flow of the variables through these operations. 
As with any programming language, Lab VIEW includes looping, ordering of 
operations, and decision making. These items are tenned 'structures' in Lab VIEW and 
are implemented visually, as displayed in Figure 2.12. For example, a while loop is 
implemented by a rectangular icon. Inside the rectangle represents operations done 
inside the loop. Operations placed outside the rectangle are done either before of after 
the loop, depending upon the wire connections. 
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[IJ 
While Loop Structure 
Items inside the structure are 
repeated until the loop is 
tem1inated by a 'False' value. 
Index, 
i=O, 1, ... 
AI 
IIULT f'T 
!'"tv"'@) 
1111111 [:::J 
Termination 
~ 
Icon Based 
All operations, structures, 
and subroutines are 
displayed as icons with wire 
connections. 
Figure 2.12: Sample LabVIEW programme structures. 
., 0 0 0 0 0 0 0 0 0 1.0, 2 [0 .. 21 ~ti 0 0 0 0 0 0 ODD 
Sequence Structure 
Structure contains several 
frames. The structure 
executes the operations in 
each frame in order. 
'OOOOOOOOOOOOOOOOOOooooOd 
'~ITrue lor 
Sequence Structure 
Structure contains several 
frames (True/False default). 
The selector chooses the 
frame to execute. 
With the advancement of PC processing power, Lab VIEW is able to perform with a 
run-time librmy. In other words, similar to Microsoft Visual Basic, Lab VIEW does not 
require compilation and linking steps before programme execution. That allows for 
faster programme debugging and development. It also allows for on-location editing and 
programming; that is, the clinical technician himself may edit the VI and adjust it as 
necessary, without requiring the presence of the developer. 
2.4.2. Patient Data Collection Programme 
The Patient Data Collection programme stores the patient's contact information, medical 
histOlY, physical characteristics, and the three physiological waveforms: respiration, 
ECG, and ABP. 
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Elect,ocar<fiogcam III 
Q]9; 
Figure 2.13: Patient data collection programme user interface. The lower three charts display the raw data 
(in DAQ counts) during physiological acquisition. 
The programme user interface is displayed in Figure 2.13. The digital controls (user 
inputs) are located above the three charts. The input is organised into patient 
information, physical characteristics, and results of the laboratOlY tests, which are 
categorised into glycaemia, lipid, and angiography. Once the information is entered, the 
technician chooses 'Begin Sampling' and the 5 minutes of physiological data is saved to 
the PC disk. During the 5 minute sampling, raw data is displayed in lower strip chatis of 
Figure 2.13. These chatis allow the technician to ensure the insh'uments are properly 
connected, operational, and collecting data as expected. Once the programme has 
collected the 5 minutes of the supine data, the technician requests the patient to stand 
and chooses the associated data type (standing), and again selects 'Begin Sampling.' 
If the technician notices a problem with the data stream from one of the instruments, the 
'AbOli Sampling' command may be used to discontinue sampling. After fixing the 
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problem, the 'Begin Sampling' command may be used again to take 5 minutes of data, 
which automatically replaces the cOlTupted data. 
The basic sampling procedure of the Patient Data Collection programme is displayed in 
Figure 2.14. Specifically, once the clinic technician selects the 'Begin Sampling' option, 
a data file on the computer hard disk is opened and the patient's histOlY, patient's 
laboratOlY results, and calibration parameters are written to the file. Then the DAQ 
board is configured for direct memory access (DMA) sampling. This allows the DAQ 
board to write the DAQ counts of the physiological measurements directly to a block of 
the PC memory without requiring communication with the PC microprocessor. That 
frees the PC microprocessor to perform other programming tasks, such as displaying the 
collected data and saving it to disk. 
Due to the physical configuration of the PC compatible mem01Y, the maximum DMA 
memory size is 64 KBytes. Since each DAQ count consists of two bytes, and three 
channels of data are sampled, the DMA block memory size is set to 10,000 samples, 
which gives a total memory size of approximately 60 KBytes (2 Byte DAQ count x 3 
Data Channels x 10,000 samples). However, that does not limit the total sampling time, 
as the DMA may be repeatedly configured to fill as many 60 KBytes memOlY blocks as 
needed. 
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Begin Sampling 
.. 
Open Data File 
.. 
Write Patient Information and Channel Calibrations 
Configure DAQ Board for DMA of Acquisition of 10,000 Samples 
Wait for DMA Buffer to Fill 
I Display ECG, ASP and Respiration Charts J 
150,000 Samples? 
No 
Yes 
End Sampling and Close Data File 
Figure 2.14: Patient data collection programme sampling procedure. 
Specifically, once the DMA memOlY buffer is filled, the programme writes the DAQ 
counts of the DMA memory buffer to the opened data file and then displays the DAQ 
counts in three strip charts: ECG, ABP, and Respiration. Since 5 minutes of 
physiological data is required and since the data is sampled at 500 Hz, the total number 
of required samples per data channel is 150,000 samples, according to Equation 2.4. 
Therefore, the DMA memOlY buffer reinitia1ized and set to automatically fill with 
additional samples. Once the desired number of samples has been taken, the DAQ board 
sampling is halted and the data file is closed. 
( . {60sec)(500 samPles) Total Samples = 5mm --. - = 150,000 Samples 
mm sec 
Equation 2.4: Total samples per channel in 5 minute sampling. 
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The sampling procedure of Figure 2.14 is coded using National Instruments' Lab VIEW. 
The VI block diagram (code) is best viewed on a large screen computer monitor as it is 
quite detailed. In accordance with the sampling procedure, the VI first opens a disk file 
based on the patient's name and the patient infonnation is organised into an array 
structure and written to the file, as per the block diagram displayed in Figure 2.15. The 
details of the file structure may be viewed in Appendix D. 
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Figure 2.15: Patient collection VI block diagram for file creation and data storage of the patient hospital 
number, telephone, physical characteristics, and laboratory results, 
After writing the patient infOlTI1ation to the disk file, the Patient Collection programme 
configures the DAQ to collect ECG, ABP, and respiration waveforms using DMA 
transfer, as per the display in Figure 2.16. Specifically, 10,000 DAQ counts are taken 
from each of the three channels and stored in a 10,000 x 3 dimensioned matrix. The 
DAQ count is stored instead of the physiological measurement in order to increase the 
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computer speed for real-time measurement and reduce the size of the data file since the 
DAQ counts consist of 2 byte integers and the physiological measurements consist of 4-
byte, floating-point decimals. 
o 0 OLd 1 ro, .21.0:(0 00_0 0 00-0 o-tn::ftfo 0 0 
Create and Write header Read & write binary data to file until maN # scans 
information to file acquired, an error occurs, or the stop button is pressed. 
-"n."-r'~"~'"~ >H~~ 
Clear Acquisitio 
and Close File ! lj ~ .. 11--I--J.:::2--f. 
'1 !D.vic'#!lu---;;J1.J ~~ 1 ~ 11'\1'. -hr"'m .. ~.mu. ······"0"='-R~.;.: ... ~.,I_ .. ,.=.~~=.c •• _1 j(;,~.rl 9-'-1" ~H H ~ i~ [c~IlCG Da.t~=J 
~ 10000 
!Harowan> Delay!:. Lool 
~ 
Configure and Start Acquisition 
{Q] 
.borl Sampfu..g 
""=' 
IT] 
Figure 2.16: Patient collection VI block diagram for DAQ configuration and data streaming of the 
physiological data to disk. 
The 10,000 DAQ counts are continually written to the data file until a total of 150,000 
samples have been saved. The DAQ counts are written for the respiration, ABP, and 
ECG, respectively. Since the each DAQ count consists of a two-byte integer, the total 
file size for the 5 minute sampling is 900 KBytes, per Equation 2.5. The initial patient 
information and laboratory results add less than 1 KByte to the data file, and so, are 
ignored in the file size calculation. 
P 'l S' (3 Ch 1 {150KSamPles)(2 Bytes) 900K B 1 e lze = anne s = ytes 
Channel Sample 
Equation 2.5: Data file size for one 5 minute sampling. 
Per the clinical procedure, each patient has six 5 minute data files taken; one for supine, 
standing, and sitting and 3 for breathing rates at 9, 12, and 15 breaths per minute. 
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Therefore, each patient requires approximately 5.4 MBytes (6 x 900 KBytes) of disk 
space. The clinic-based computer contains a 40 GByte hard disk, of which the operating 
system and Lab VIEW take approximately 1 GByte of disk space. That allows for 
approximately 7,400 (39 GByte 15.4 MByte) patients to be screened and stored. 
2.4.3. Patient Data Review Programme 
Once the 6 sets of physiological data have been collected, the technician may review the 
data using the 'Data Display' programme as shown in Figure 2.17. This allows the 
technician to quickly determine if any acquisition problems OCCUlTed during the session, 
by glancing through the physiological wavefol1ns. If a problem is noted, the technician 
has the patient immediately available to re-takes the affected 5 minute set. Requesting 
patients to return to the clinic for further tests is often problematic. 
Each 5 minute data set is stored in a separate file. The technician opens one of the 6 data 
sets: supine, standing, sitting, and sitting at 9, 12, and 15 breaths per minute and views 
the physiological waveforms. Due to limitations in the chart structure, only 3000 
samples are displayed at a time. And so, the technician steps through the entire data set 
by selecting 'Next Set' until the end of the data set is reached. 
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Figure 2.17: Patient data review programme user interface. 
The Patient Data review VI block diagram is partially displayed in Figure 2.lS. The VI 
queries the user's choice of filename and disk location. Then the VI computes the 
number of bytes in the patient's history in order to skip to the physiological waveform 
data. Before displaying the physiological data, the VI uses the calibration infolluation to 
compute the physiological measurement from the stored DAQ counts, per Figure 2.lS. 
Lastly, the VI displays 3000 samples of each physiological waveform for the technician 
to review. A sequence structure is used as the first frame reads the physiological data 
from the file and the second frame waits for the user to review the data before reading, 
calibrating, and displaying the next 3000 samples. 
S3 
., 0 0 0 0 0 0 0 0 0 0 0 0 0 oooooooooooon 
., cr-o 0 o~cn::n::n::rtltr 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
III 
Read, scale &: chart binary data until end of 
file, an error occurs, or the stop button 
Figure 2.18: Patient Data review VI partial block diagram. 
2.4.4. Patient Laboratory Data Edit Programme 
! _f::....... ..... r::=:::l(-. 
... '1...-;. .............. : ~ 
dose file and 
notify user of 
any errors 
Occasionally, the patient's laboratOlY results are not available at the time of the 
physiological acquisition in clinic. Instead of requiring the patient to wait for the results 
before collecting the physiological waveforms, the Patient Edit VI allows the technician 
to open a saved data set and edit the non-physiological measurement data. Figure 2.19 
displays the user interface of the VI. Note that the technician is not allowed to edit the 
patient's name and telephone number. 
The main structure used in the Patient Edit VI block diagram is a sequence structure. 
The first frame opens the data file and reads the patient name, telephone number, and 
information concerning the patient's history, characteristics, and laboratOlY results, as 
shown in Figure 2.20. The VI also allows the calibration coefficients and sampling 
frequency to be edited. 
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Figure 2.19: Patient laboratory results edit VI user interface. 
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Figure 2.20: Patient Edit VI block diagram, sequence O. 
Once the technician has completed the necessary changes, the 'Save Info' command is 
selected and the second frame of the sequence then executed, as shown in Figure 2.21. 
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Here, the control values are combine into an anay and written to the same file, thus over 
writing the old information with the new. 
'00000000000000000000000000 1 0 .. 2 0000000000000000000000000 
IS3 
True 
'000 0000000 0 o 0 .. 1 00 000 0000 
+ 
~!ITt'\:v@ 
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D--· 
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Figure 2.21: Patient Edit VI block diagram, sequence 1. 
2.4.5. Patient Data Extraction Programme for MathWorks' MatLab 
MathWorks' mathematical programme, MatLab [59], is used to develop and test the 
signal-processing algorithm for extracting and analyzing the HRV from the EeG. 
Therefore, a custom utility was developed to read the patient's six data sets and create 
WaVefOlTI1 files that are MatLab compatible. Once the best analysis algorithm has been 
developed, it may be easily implemented by LabVIEW. 
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Figure 2.22: Patient data extract for MatLab VI user interface. 
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Figure 2.23: Data extract VI block diagram to open the patient 5 minute data set, create a file of 
laboratory results, and determine the calibration equations. 
The VI user interface is displayed in Figure 2.22. When executed, the VI first queries 
the user to select the patient data to process. The technician may select any of the six 
5 minute data sets, as the utility is able to determine all the data set file names from any 
one data set. Once the utility has detem1ined the patient's name, it processes all the data 
sets. Once a patient is selected, the VI creates a new directory using the patient's name 
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and then creates a file entitled 'LD' which contains the patient's information and 
laboratory results, as seen in Figure 2.23. 
Next the VI, reads each of the six data sets and creates cOlTesponding, calibrated, 
MatLab compatible files entitled: SP, SD, ST, S9, S12, and S15. The determination of 
the calibration equations is seen in Figure 2.23 and Figure 2.24 displays the calibration 
implementation. Note the text file icon, which is used to save the data sets in a MatLab 
compatible file. 
·'i"'j"E>' 
OJ 
Read, scale 8.: chart binary data until end of 
file, an error occurs, or the stop button 
dose file and 
notify user of 
any errors 
Figure 2,24: Patient data extract VI block diagram which reads 3000 samples from the data set, applies 
the calibration equations, and then saves the physiological measurements to a MatLab compatible file, 
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2.4.6. Patient Respiration Timer Programme 
Three of the acquisition sets require the patient to breathe at a particular rate. In order to 
accomplish this, a 'Respiration Timer' VI was written to guide the patient's breathing 
rate. The VI user interface is displayed in Figure 2.25 and allows the technician to set 
the respiration at 9, 12, or 15 breaths per minute. The patient is guided by following the 
red and blue bars, which either indicate the patient to breathe in or out, accordingly. The 
VI uses five colour bars so that the patient can better gauge their breathing and knows 
approximately how much time remains to the end of the breath cycle. 
9 BREATHS PER MINUTE I~!LIII pROGRAf'"1J 
Figure 2.25: Breath timer VI user interface used to guide the patient in breathing 9, 12, or 15 breaths per 
minute. The 'BREATH IN' bar is red and the 'BREATH OUT' bar is blue. 
The Breath Timer was easily implemented in LabVIEW. The VI block diagram may be 
viewed in Figure 2.26. The VI employs a continuous while loop and Boolean shift-
register. The red 'BREATH IN' and blue 'BREATH OUT' bars are Boolean lights that 
are toggled by True and False values, respectively. Each iteration of the loop shifts 
either a True or False value, and so, the VI either turns on all the 'BREATH IN' or 
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'BREATH OUT' bars after five iterations. Therefore, one full breath occurs after 10 loop 
iterations. The loop timing is set according to the selection of the constant value in the 
Case structure. The timer setting in Figure 2.26 is for 9 breaths per minute, as per the 
calculation in Equation 2.6. The timer values for 12 and 15 breaths per minute are 
displayed in Equation 2.7. 
Ill! I '~I 
:' .... 1. 
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Figure 2.26: Breath timer VI block diagram. 
R .. (lLOoP)(lBreath)(1000ms)(60sec) 9 ,sf esplratlOn = -- =:: Breathtn · 667ms 10Loops sec min - nun 
Equation 2.6: Respiration computation based upon the timer value. 
Timer
12 
= ( min )( 1 Breath )(1000ms)(60~ec) = 500ms 
l2Breaths 10 Loops sec mm 
Timer
15 
= ( min )( 1 Breath )(1000ms)(60~ec) = 400ms 
1 5 Breaths 10Loops sec mm 
Equation 2.7: Timer computation for 12 and 15 breaths per minutes. 
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2.5. System Observations 
Note the physiological waveforms displayed in the Patient Data Review VI of Figure 
2.17. The top chart displays the voltage of the respiration monitor. In comparison to the 
other chalts, it is easily observable that the respiration frequency is far less than the 
ABP or ECG. Specifically, the number of samples between the respiration voltage 
peaks, as viewed in the top chart of Figure 2.17, is approximately 2000. Therefore, 
considering the sampling frequency and according to Equation 2.8, the patient 
respiration is about 15 breaths per minute, which is reasonable for humans. 
R .. (I Breath )(500 samPles)(60sec) 1 1,,/ e spuatlOn ;:::; -- = 5 Breat '7n . 
2000 Samples sec min mill 
Equation 2.8: Computation of approximate respiration from patient data. 
The middle chatt of Figure 2.17 displays ABP with a nomlal morphology. Besides 
regular systolic and diastolic pressure, the diacritic notch is observable. From the chatt, 
the systolic pressure is approximately 140 mmHg, the diastolic pressure is 
approximately 75 mmHg and mean average pressure is approximately 120 mmHg. 
These results are reasonable for a human. As far as the heart rate, the number of samples 
per ABP cycle and Equation 2.9 are used to compute the rate to be approximately 
70 BPM, which is also reasonable. 
Heart Rate;:::; (7 ABPCYc1es)(500Samples)(60~ec) = 70 Beat%'in 
3000Samples sec mm 
Equation 2.9: Computation ofhemi rate from ABP. 
The bottom chatt of Figure 2.17 displays nOlmal ECG. The characteristics of the ECG 
are explained in the next chapter. In brief, the ECG consists of three wavelets, termed 
the P-wave, QRS complex, and T-wave, respectively. In observing the collected ECG, 
the QRS complex and T -wave are easily observable. Furthelmore, the subtle P-wave is 
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observable. The P-wave occurs prior to the QRS complex and after diastole, the cardiac 
rest period, which is defined as beginning after completion of the T-wave. Similar to the 
ABP, the heali rate (Equation 2.10) is computed to be approximately 70 BPM. 
Heali Rate:::::: (7ECGCYcles)(500Samples)(60~ec) = 70 Beat%lin 
3000Samples sec mm 
Equation 2.10: Computation of heart rate from ECG. 
Lastly, in relation to the ABP and ECG chalis of Figure 2.17, note that the ABP cycle 
lags the ECG QRS cycle. This is reasonable, considering human physiology, as the 
cardiac ventricles are first depolarised during the QRS complex of the ECG. Once 
depolarised, the cardiac muscle responds by contracting and initiates an increase in BP. 
Furthermore, the ABP is measured at the extremity (index finger) and so there is transit 
time between the he ali and finger for the pressure wave to travel. 
2.6. Summary 
The goal of the research is to study the effectiveness of using extemal physiological 
data to assess the patient's DM and CHD condition. In order to enable this research, a 
clinical data acquisition is designed and implemented. Specifically, the DAQ system 
acquires respiration, ABP, and ECG non-invasively from the patient in a clinical setting. 
Fulihermore, the system is based on a low-cost PC that employs the graphical coding 
development package Lab VIEW, for configuring the DAQ, storing the data, and 
executing utility programmes. 
Use of LabVIEW frees dependence upon rigid, English-based code and enables visual 
coding through the use of wires and symbolic icons. Also, considering the 
computational power of today's PCs, Lab VIEW is able to operate through run-time 
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libraries, which eliminated the need for compiling and linking of modules. Instead, the 
VI may be easily changed in the clinical setting and executed directed. 
Besides DAQ and data storage operations, Lab VIEW includes the necessary operations 
and subroutines for implementation of complex data analysis routines. That enables 
future version of the Patient Collection VI to not only acquire the patient's physiological 
data, but also analyse and diagnose the condition. FUlihermore, Lab VIEW contains 
advanced communication subroutines that allow future versions of the Patient 
Collection VI to not only store the patient data remotely via the intemet but also be 
remotely monitored and accessed by the doctorial staff and maintenance engineer. 
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Chapter 3 - HRV Extraction from Electrocardiogram 
3.1. Introduction 
The electro-physiological ECG signal is acquired from the patient; however it is the 
HRV signal that used to assess the patient condition. Therefore, the HRV information 
must be extracted from the ECG signal. Specifically, the ECG QRS complexes are 
detected and the individual beat, heart periods are determined. Since beat heart period 
(HP) varies in time, the resulting data is interpolated for equal spacing in time. Lastly, 
the trend is removed in order to highlight the variability in the signal, as per the 
algorithm in Figure 3.1. 
5-Minute Strip of Lead II Electrocardiogram Data 
QRS Beat Detection 
Computation of Cardiac Cycle Period 
Interpolation to 5Hz Sampling Freq, Equally Spaced 
I 
Removal of Trend 
1 
Figure 3.1: Algorithm to process HRV from ECG. 
3.2. ECG Characteristics 
Before processing algorithms are developed, the general characteristics of the 
physiological signal are investigated in order to make use of a priori infom1ation. This 
knowledge enables the designer to produce more robust algorithms. This is patiicularly 
true for algorithms that incorporate peak detection. 
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The ECG signal is assumed to be semi-periodic and wide-sense stationary. That is to 
say, the peak event occurs on a regular based interval and, although there may be time 
dependant wavelets in the signal, as a whole, the signal is time-invariant. For example, 
the ECG signal consists of P-QRS-T wavelets (see Figure 3.2), which are time-
dependent as far as their shape and duration, but for a 5 minute ECG signal, the 
individual complexes are viewed as stationary events in a periodic signal. Although this 
is generally true for most physiological signals, some have suggested that parameters 
estimated from the signal are not necessary periodic or time-invariant. [60] 
R 
p T 
Q 
s 
Figure 3.2: ECG beat with labelled wavelets. 
Beyond these characteristics, it is assumed that the ECG spectrum is band-limited, 
which means the signal information consists of a limited range of frequencies. For 
example, it has been shown that most of the ECG information is in the range 0[0.05 Hz 
to 100 Hz. [61] Note that these spectral limits are set for human ECG and different 
species have different spectral bands. 
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In order to improve detection of the QRS complex, the maximum slope of the R-wave is 
used as a detection point instead of the maximum R-wave deflection. Consider the two 
ECG beats cycles in Figure 3.3. The individual samples are plotted in order to highlight 
the fact that the R-wave peaks are clipped due to either saturation of the pre-amplifier 
output or maximum quantisation of the analogue to digital converter. Either way, the 
R-wave peak is detected with at best ±5 sample resolution, which gives a measurement 
error of ± 10 msec, since the sample period is 2 msec. However, the maximum slope of 
the R-wave is detected within ±l sample, also shown in Figure 3.3, which gives a 
resolution of ±2 msec. Therefore, use of the maximum slope of the R-wave enhances 
the precision in determining the associated heart period. [62] [63] 
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Figure 3.3: ECG with saturated peaks and marked maximum slope. 
Besides problems of peak saturation, detection of the leading edge eliminates the need 
to account for baseline offset and baseline wander, where the ECG baseline slowly 
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increases or decreases over time. This is due to the fact that the baseline shift and slow 
baseline wander are approximately constant and, therefore, approach zero during 
differentiation. 
In order to detect the leading edge of the R-Wave, the ECG differential is computed 
according to the difference equation, as shown in Equation 3.1. The time difference 
between the samples is not considered in the difference equation since it is constant for 
all samples of the ECG. 
Yi = Xi -Xi- 1 
Equation 3.1: Sample difference equation, which approximates the differential. 
However, the differential approximation of Equation 3.1 also magnifies high frequency 
components in the ECG, such as the myoelectric (EMG) interference (muscle artefact). 
A priori considerations of the ECG spectrum (0.05 to 100 Hz), allow for use of another 
function that approximates the differential in the frequencies of interest and then 
approaches zero for higher frequencies. One such function is a 5-point secant (Equation 
3.2), which approximates the ECG differential without amplifying the signal noise, as 
seen in Figure 3.4. 
I y.=2x.+lx'I+Ox'2- lx '3- 2x '4 ------- I 
111- 1- 1- 1- ~
Equation 3,2: 5-point secant difference equation used to approximate the differential. 
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Figure 3.4: Spectrum response for differential and secant difference equations. 
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Specifically, note that less than 0.2 Hz of the nOlmalized frequency, the secant function 
is virtually identical to the differential. With a sampling frequency of 500 Hz, this 
means that frequencies less than 20% of 500 Hz (100 Hz) are, in effect, differentiated 
while frequencies greater than 100 Hz are reduced; effectively, low pass filtering the 
data and reducing the higher frequency noise. Therefore, not only is the approximate 
differential computed in order to use the peak detection algorithm to determine the 
maximum slope, but also any higher frequency noise is reduced to ensure more robust 
detection. Figure 3.5 displays the positive, 5-point secant of an EeG. Since the secant 
was taken in order to detect the leading edge of the R-wave, the negative values are 
discarded. Note the enhancement of the peaks in relation to the high frequency noise at 
the baseline. These peaks are then used to detect the leading edge of the R-wave and, 
subsequently, the time between sequential R-waves, which is the HR. 
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Figure 3.5: ECG positive secant. 
3.3. Peak Detection 
Todd and Andrews have gone far in describing physiological signals as they relate to 
peak detection. [64] In summaty, a physiological signal is comprised of a sequential 
data series of numbers. A peak is defined as any element in the data series that 
dominates both a preceding element and a subsequent element. 
In mathematical tem1s, peaks are defined as local maxima. Specifically, a peak is a 
maximum value between two consecutive local mlmma. Similarly, a trough is a 
minimum value between two consecutive local maxima. To be considered a peak, a 
sample value must be at least 0 greater than a trough. This threshold value, 0, is also 
used to define a trough as the minimum value less than 0 between two consecutive local 
maxima, per Equation 3.3. 
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Xp =XT +O::S:X p nX T +O::S:X p J I J 1+1 j 
XT =Xp -O;::::XT nXp -O;::::XT I J 1 J+l 1 
Equation 3.3: Mathematical definition ofa local maximum and minimum. 
The Matlab [65], m-file algorithm of Figure 1.12 implements the above peak and trough 
definition. The operation of the algorithm depends upon the value chosen for the 
threshold. Visual inspection of the data allows for easy threshold selection. However, 
this requires supplemental training of clinical staff acquiring the data and additional 
time with the patient. Automated threshold estimation greatly improves the heart rate 
algorithm and simplifies the clinical procedure. 
function [P,T] = PTDetect(x, E) 
P = []; T = []; a = 1; b = 1; i 0; d 0; 
xL = length (x) ; 
while (i -= xL) 
i = i + 1; 
if (d == 0) 
if (x(a) >= (x(i) + E)) 
d = 2; 
elseif (x(i) >= (x(b) + E)) 
d 1; 
end; 
if (x(a) <= x(i)) 
a = i; 
elseif (x(i) <= x(b)) 
b = i; 
end; 
elseif (d==l) 
if (x(a) <= x(i)) 
a = ii 
elseif (x(a) >= (x(i) + E)) 
P = [P a]; b = i; d 2; 
end; 
elseif (d==2) 
if (x(i) <= x(b)) 
b = i; 
elseif (x(i) >= (x (b) + E)) 
T = [T b]; a = i; d 1; 
end; 
end; 
end; 
Figure 3.6: Peak detection algorithm. 
Since the leading edge of the R-wave is being detected, only positive slopes of the ECG 
are estimated. These slope values are then divided into two clusters. One cluster consists 
of the peaks, which are known to refer to the ECG R-wave. The other cluster consists of 
the positive slope values near zero. 
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In order to separate the positive slope values into two clusters, unsupervised learning, 
nearest neighbour criteria clustering is used. Unsupervised learning may be used since it 
is known that two clusters are desired. The nearest neighbour criterion is chosen since it 
requires far less calculation than sum-of-squared-error or Bayesian maximum likelihood 
criteria. [66] 
The nearest neighbour criterion is implemented as the absolute difference between a 
sample and cluster means. The sample is assigned to the cluster mean with smallest 
difference. Once all the samples have been assigned, new cluster means are determined 
and samples are again classified to the nearest cluster mean. Algorithm termination 
occurs when the change in the cluster means is less than E. Figure 3.7 displays the 
Matlab m-file implementation of the unsupervised learning, two cluster classifier. 
function [cl, c2]=twoclass(x, e) 
cl=x(l); lastcl=cl; c2=x(2); lastc2=c2; 
while 1 
classl=[]; class2=[]; 
for i=l:length(x) 
if (abs(cl-x(i)) < abs(c2-x(i))) 
classl= [classl x(i)]; 
else 
class2 = [class2 x(i)]; 
end; 
end; 
c2=mean(class2); cl=mean(classl); 
if (abs(lastc2-c2) < e) & (abs(lastcl-cl) < e) 
return; 
end; 
lastc2 = c2; lastcl cl; 
end 
Figure 3.7: Two class clustering algorithm. 
Once the cluster means are determined, the larger cluster mean is the centre of the peak 
data and used as the threshold for the peak detection algorithm. 
Figure 3.8 displays the results of the peak detection algorithm with auto-threshold 
setting. Specifically, the secant-estimated derivative of 12 consecutive QRS complexes 
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is displayed with the threshold marked as a straight line and the peaks marked with 
circles. 
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Figure 3.8: ECG secant estimate of the derivative with marked threshold and peak detections. 
3.3.1. Peak Detection Enhancement - Linear Filtering 
Since the ECG spectrum is assumed to be band-limited to the range 0.5 to 100 Hz, low 
pass filtering may be used to reduce noise above 100 Hz. Noise above 100 Hz is often 
associated with EMG interference and harmonics of 220 V RMS power. Linear filtering, 
Finite Impulse Filtering (FIR), may be used to implement a low pass filter effect on the 
samples while maintaining a linear phase delay between samples. In other words, the 
higher frequency data is reduced in magnitude, but the same relative time delay between 
samples is preserved. [67] [68] 
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Equation 3.4 displays the filtering equation for a 10th order FIR filter, where the bi 
coefficients are the filter coefficients. The coefficients are chosen in order to reduce the 
amplitudes of frequencies greater than 150 Hz, which implies a low pass filter (LPF) 
implementation. 
Yi = bOXi + b1x i_1 + b 2x i_2 + b3x i_3 + b 4x i_4 + bSxi_S + b 6x i_6 + b 7x i_7 + b 8x i_8 + b 9x i_9 
Equation 3.4: 10th order FIR filter difference equation. 
Since the filter of Equation 3.4 consists of only ten coefficients, the filter tends to 
unevenly reduce the higher amplitudes. This is due to the implication that the filter is 
multiplied by a square wave, which gives rise to a sinc function in the frequency 
domain. Hamming, and others, have shown that the sinc function side-lobes may be 
significantly reduced if the filter coefficients, bi, are adjusted by a windowing operation, 
as show in Equation 3.5. 
fi-~ b, (0.54-=0.46 cos(in N',] 
Equation 3.5: Hamming window implementation. 
In Equation 3.5, N is the filter order and ranges from 0 to N-l. As an example 
application, typical ECG is corrupted with n0l111al random noise and displayed in Figure 
3.9. The a priori spectral infOlmation and LPF are applied to the noisy ECG signal and 
result is displayed in Figure 3.10. Note the evident reduction in the high frequency noise 
at the baseline. 
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Figure 3.9: Sample ECG corrupted with random noise. 
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Figure 3.10: FIR filtered ECG. 
3.3.2. Peak Detection Enhancement - Refractory 
Once a peak has been detected, a refractory or blanking time may be employed in order 
to ensure against false, early detection. Specifically, refractOlY halts possible peak 
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detection until such a time that a peak may be possible. The time of blanking is set using 
a priori information of the physiological data. Figure 3.11 displays the Matlab 
implementation of the modified peak detection algorithm. The additional input defines 
the number samples that must pass before a new peak may be detected. 
In relation to the ECG signal, occasionally the cardiac re-polarisation, T-wave, is large 
enough to be detected as an R-wave, as shown in Figure 3.12. Needless to say, this 
misdetection would greatly affect the HRV. 
function [P,T] = PTRDetect(Q, E, R) 
P = []; T = []; a = 1; b = 1; 
Rp = -R+1; Rt = -R+1; 
i = 0; d = 0; 
QL = length(Q); 
while (i -= QL) 
i = i + 1; 
if (d == 0) 
if (Q(a) >= (Q(i) + E)) 
d = 2; 
elseif (Q(i) >= (Q(b) + E)) 
d = 1; 
end; 
if (Q(a) <= Q(i)) 
a = ii 
elseif (Q(i) <= Q(b)) 
b = ii 
end; 
e1seif (d==l) 
if (Q(a) <= Q(i)) 
a i; 
elseif (Q(a) >= (Q(i) + E)) 
if (a > Rp+R) 
P = [P a]; Rp = a; 
end; 
b = i; d 2; 
end; 
e1seif (d==2) 
if (Q(i) <= Q(b)) 
b = ii 
elseif (Q(i) >= (Q(b) + E)) 
if (b > Rt+R) 
T = [T b]; Rt = b; 
end; 
a = i: d = 1; 
end; 
end; 
end; 
Figure 3.11: Refractory modified peak detection algorithm. 
Since it is known that the ECG signal is from a human, the maximum expected heart 
rate in a clinical screening session is approximately 150 BPM. [69] Therefore, a 
refractory of 400 msec may be used to safely avoid the secondmy peak. Using the 
105 
modified peak detection algorithm and a known sampling frequency of 500 Hz, the 
refractory tuning is computed according to Equation 3.6. 
( samPles)( {sec) RefractOlY = 500 400msec = 200 Samples sec 1000nlsec 
Equation 3.6: Computation of sample refractory based upon human physiology. 
The modified peak detection with refractory algorithm is to the ECG signal with high 
T-wave deflections of Figure 3.12. Specifically, the ECG secant derivative estimate is 
shown and it is noted that the T-wave approaches the height of the R-wave. The peak 
detection algorithm output is also marked on the chart and is successful in avoiding the 
T-wave deflections. 
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Figure 3.12: ECG derivative estimate with detected R-wave peaks and T-wave peaks avoided using 
refractory. 
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3.4. HRV Computation 
Once the ECG QRS complexes have been detected, the individual beat periods are 
computed as the difference between the time indexes of consequent R-wave, as shown 
in Figure 3.13. Since the period changes from one beat to the next, both the period and 
the time of the start of the period are recorded. As a convention, the beat period is 
assigned to the time index of the initial R-wave. 
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Figure 3.13: Two ECG beats with individual periods marked. 
The HR is defined with units of beats per minute. Therefore, if the HP for one beat is 
650 ms, then the HR for one beat is 92 Beats/min, per Equation 3.7. Note that the HR 
and HP are inversely propOliional to one another and, though they contain the same 
infOlmation, give reciprocal distributions. That is, as the HP increases, the HR 
decreases, and visa versa. 
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HR = ( 1 Beat )( 1 000 ms)( 60 ~ec) =' 92 Be~ts 
650ms sec mm mm 
Equation 3.7: Computation of the HR for one beat, given HP for one beat. 
Although the HP and HR are related, the HP is prefened for the HRV signal as it has 
been shown to give linear response to vagal stimulation, which slows the rate of cardiac 
contractions, while the HP gives a hyperbolic response. [70] Some have proved that 
logarithmic HP and HR give the same distribution, as shown in Equation 3.8, which 
eliminates concerns over which to use for the HRV signal. [71] 
HROC(~p ) 
10g(HR) oc 10g( ~p ) = -log(HP) 
Equation 3.8: Comparison of logarithmic HR and HP. 
Even so, the goal of this study is to detemline the best analyses to highlight differences 
between the patient conditions. The larger the difference, the better the classifier is able 
to assess the patient. For this reason, the author has chosen to focus on use of the HP per 
beat for the HRV signal. 
3.5. Outlier Removal 
Ectopic beats and skipped beats by the patient's heart give rise to discontinuities in the 
HRV signal. Ectopic beats are often premature ventricular contractions (PVC), shown in 
Figure 3.14, which, although do not resemble the typical P-QRS-T beat, are detected by 
the algorithm and significantly disrupt the HRV signal. In order to analyse the HRV 
signal, these discontinuities, termed outliers, are removed. 
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Figure 3.14: Sample ECG with Pvc. Note the disrupted effect of the HR. 
Outlying HR values differ statistically from the HRV signal as a whole. Traditionally, 
outliers are defined as samples that are more than 3 standard deviations from the sample 
mean, as shown in Equation 3.9. [72] 
Outliel; == {Xi > ~ + 3( a J 
Xi <x+3(aJ 
where,~=...L ~ VNi>~ _(~X.)2 
N .L.Xi' and a = i=1 .L. 1 i=1 x 1=1 N2 
Equation 3.9: Traditional outlier limits based upon sample mean and standard deviation. 
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Figure 3.15: HRV Signal with possible outlying sample, 162, marked. 
F or example, Figure 3.15 displays the HRV waveform for a 5 minute EeG. It is 
suspected that sample 162 is an outlying sample since it differs from the remainder of 
the data set. The set is approximately nonnal in its distribution, as shown in Figure 3.16, 
and the following statistics are computed in Figure 3.17. According to the statistics, 
sample 162 is less than outlier limit, and so, is marked as an outlier. Once the outlying 
sample is removed, interpolation is used to complete the data set and account for the 
missing sample. [73] 
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Figure 3.16: HRV sample distribution. 
850 
Statistic Units in msec 
Sample mean 850 
Sample standard deviation 33 
Upper outlier limit 949 
Lower outlier limit 751 
Samplel62 value 720 
Figure 3.17: HRV statistics for determining outlier conditions. 
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In recent years, it has been noted that outlier identification based upon the sample mean 
and standard deviation has the intrinsic problem of using the outlier values in computing 
the upper and lower limits. [74] Instead, the sample median and inter-quartile range are 
used as estimates for the sample mean and standard deviation. The median is defined as 
the 50% percentile of the sample values. The inter-quartile range is defined as the 
difference between the 25% and 75% percentiles of the sample values. Using these 
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definitions, an outlier is defined as any sample values outside the following limits of 
Equation 3.10. [75] 
. _ {Xi> median(X)+ 3(range(X)) 
OutlIer. = () ( ()) 
I Xi < median X - 3 range X 
Equation 3.10: Outlier limits defined by the sample median and inter-quartile range. 
In Equation 3.10, X is the set of all the sample values. This outlier definition has the 
strong advantage of not using any possible outlier values in computing the upper and 
lower limit. Considering the previous HRV signal, sample 162 is again suspected as 
COlTUpt due to an ectopic or skipped beat, since the following statistics are computed in 
Figure 3.18, and sample 162 is less than the lower outlier limit. 
Statistic Units in msec 
Sample median 848 
Sample inter-quartile range 38 
Upper outlier limit 962 
Lower outlier limit 734 
Samplel62 value 720 
Figure 3.18: HRV statistics for determining outlier conditions. 
However, upon careful inspection of the ECG QRS detection algorithm, it was 
determined that no ectopic or skipped beats occulTed. Also, it was confirmed that the 
previously introduced algorithm detected all the QRS complexes cOlTectly and that the 
HRV signal was physiologically COlTect. Specifically, the observable difference III 
sample 162 is due to a sudden change in the cardiac rhythm, which is normal. 
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These statistical based outlier definitions assume time-invariant data. That is, that the 
sample statistics do not change with time. Over the 5 minutes of ECG collection, it was 
noted that the patient's heart rate continuous adjusted for the cardiac load, which is a 
normal physiological response. Therefore, most statistical based methods for outlier 
identification are not valid and instead a priori info1TI1ation is used in order to determine 
appropriate limits. 
Specifically, human physiology is considered for determining the upper and lower limits 
of acceptable HRV samples. It is assumed that the HR does not increase or decrease by 
50% over a 5 minute period while the patient is resting. [76] Using this a priori 
information, the following limits are computed and displayed in Figure 3.19. As per 
these calculations, it is determined that sample 162 is not an outlying sample and this 
outlier removal definition is implemented in the algorithm to extract the HRV 
information from the ECG signal. 
Statistic Units in msec 
Sample median 848 
Upper outlier limit (50% above median) 1270 
Lower outlier limit (50% below median) 424 
Samplel62 value 720 
Figure 3.19: HRV statistics for determining outlier conditions. 
3.6. Interpolation 
Most digital signal processing routines assume the data is equally spaced in time. As 
previously mentioned, the initial HRV data set consists of both time and period 
info1TI1ation. In order to produce equally spaced data, mathematical interpolation is 
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used. Also, since the maximum frequency of interest is less than 2.5 Hz, a sampling 
frequency of 5 Hz is chosen, as per the Nyquist sampling theorem. 
Interpolation is accomplished by fitting a function to known data points, termed 'knots', 
and then using the function to compute the equally spaced data points. There are many 
interpolation algorithms such as the Lagrange polynomial interpolators. The author 
chose to use a cubic spline implementation as it minimizes overshoot and ringing 
associated with polynomial functions. Figure 3.20 displays 10 seconds of the original 
HP data computed from the EeG and equally spaced, interpolated HP data. 
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Figure 3.20: ECG HP data overlaid with 5 Hz interpolated HP. 
3.7. Trend Removal 
10 
HP 
• Interpolated HP 
The average of the HRV signal corresponds to the average heart rate, which has been 
shown to be of little interest in classifying the patient condition. In order to better 
analyse the HRV signal, the trend is removed. Specifically, HRV signal information 
near 0 Hz is removed. 
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There are many methods of removing the signal trend. A quick and common one is to 
subtract the sample mean (or median) from each sample, as per Equation 3.11. A more 
generalised form is to subtract the best straight line determined by least squares, per 
Equation 3.12. 
N 
Yi = Xi - X where ~ =-1:i 2:>i 
i~l 
Equation 3.11: Trend removal via subtraction of the sample mean. 
Yi =xi -(mXi + b) 
where 
N(tXiYi)(tXi)(tYi) 
m~ N(t,X:)-(t,x,J and 
b ~ (t, y.)(t, x;) -(t,x,)( t,x,y,) 
1t,x; )-(t,x,)' 
Equation 3. I 2: Trend removal via subtraction of the best straight line. 
However, considering the HRV frequencies of interest, which is approximately O.OlHz 
and greater, a moving average subtraction, or a high pass filter (HPF), may be used to 
remove the unwanted HRV information. Filtering allows for the selection of the desired 
signal information and removal of noise. In this case, a HPF is used to pass the desired 
HRV signal infOlmation and reduce the low frequency HRV trend, per Figure 3.21. [77] 
HRV Signal 
High Pass Filter 
O.OIHz Cutoff 
O.OIH Frequency 
Figure 3.21: HRV trend removal via a HPF. 
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HRV Signal Less Trend 
A simple implementation of HPF of this technique may be done using the application of 
the WT. [78] The wavelet decomposition is implemented using a matched HPF and 
LPF, per Figure 3.22. At each level of the decomposition, the HPF successively reduces 
the passed HRV spectrum. Considering the implementation in Figure 3.22, the 
decomposition is carried out to level 7, since at that level, detail frequency range would 
be approximately 0.02 to 0.04 Hz, and the approximation would be from 0 to 0.02 Hz. 
The approximation coefficients are then discarded, and thus, the HRV signal trend is 
removed. 
The advantage of wavelet based, HR V trend removal lies in the reduction of signal 
processing complexity. Instead of processing the HRV signal to remove the trend, the 
wavelet decomposition may be used to analyse the HRV signal and remove the trend in 
the same step. Further application of the WT to the HRV signal may be found in 
Chapter 4. 
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HRV[n] Signal with Frequency range 0 to 2.5 Hz 
l.3 to 2.5 Hz 
Levell Coefficients 
Level 2 Coefficients 
0.31 to 0.63 Hz 
Level 3 Coefficients 
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••• 
Figure 3.22: HRV wavelet decomposition using high and low pass filters, g and h, respectively. 
3.8. Summary 
It has been shown that HRV may be extracted from ECG. A priori information of the 
ECG characteristics and human physiology are used to enhance QRS detection, and 
thus, computation of the HRV signal. Outlier analysis is used for correction of ectopic 
and missing beats. Although traditional and median based outlier removal was 
investigated, neither proved satisfactory due to the time-variant nature of the HRV 
signal. Instead, human physiology is used to compute acceptable outlier limits. Once 
outlying samples are removed, spline based interpolation is used to increase the 
sampling frequency and to equally space the data in time. Each of these steps of the 
algorithm to detelmine HRV from the ECG is implemented using MatLab, as shown in 
Figure 3.23. 
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function hp = hrvecg(ecg); 
% Extract equally spaced heart period data from ECG 
% 
% usage hp hrvecg(ecg) 
% 
% ecg = electrocardiogram data, 500 Hz sampling assumed 
% hp = heart period, 5 Hz sampling frequency 
% 
% 5 point secant based peak detector used. The empty set is returned for an error. 
hp = [); 
% DETERMINE THE R-WAVE SLOPE 
secg = secant(ecg, 0.002); 
% DETERMINE PEAK THRESHOLD BASED UPON TWO-CLASS UNSUPERVISED CLASS SEPARATION 
asecg=secg(secg>15); 
[c1 c2 it)=twoclass(asecg, 10); 
% DETERMINE MAXIMUM SLOPE LOCATION 
[Peaks, V) PTRDetect(secg, 2*abs(c1-c2), 200); 
Peaks Peaks' ; 
pk1en length(Peaks) ; 
if pklen > 2 
% SET THE TIME INDEX 
hpx = zeros (pklen-1, 2); 
hpx(:,l) = Peaks (1:pklen-1) ; 
% DETERMINE THE BEAT HEART PERIODS 
hpx(:,2) Peaks (2:pklen) - Peaks (1:pklen-1) ; 
% REMOVE OUTLYING SAMPLES 
hpx = HRVOutlier(hpx); 
% INTERPOLATE TO 5HZ SAMPLING 
i = 0:100: (150000-100); 
hp = spline (hpx ( : , 1), hpx ( : ,2), i)'; 
end; 
Figure 3.23: MatLab algorithm to determine the HRV signal from ECG. 
Lastly, in order to enhance the analysis of the signal variability and reduce algorithm 
complexity, the HRV signal trend is removed. Although linear regression or a HPF may 
be used to remove the trend, wavelet decomposition allows for easy trend removal and 
characterisation of the HRV signal in the same step. Therefore, the MatLab algorithm of 
Figure 3.23 does not include trend removal as this step is integrated with the HRV 
analysis of Chapter 4. 
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Chapter 4 - HRV Analysis 
4.1. Introduction 
The major goal of this research is to determine the effectiveness of using the HRV 
signal as a basis for screening patients for DM and CHD. The HRV signal is extracted 
from the ECG signal and consists of approximately 350 samples for each patient action, 
as explained in Chapter 2. In order to enhance the effectiveness of the screening, various 
features are computed from the HRV signal. Specifically, features are computed that 
best distinguish between diseased and non-diseased patients. 
The type features computed are categorised into those extracted from the HRV time 
domain infomlation, those from the HRV frequency domain information, and those 
from the HRV time-frequency domain infomlation, as per the discussions in Chapter 1. 
The extracted features are con-elated in order to detemline which provide redundant 
information. 
4.2. Time Domain Analysis 
Time domain analyses of the HRV signal includes STD, rMSSD, ZC, histogram and 
phase analysis. [79] [80] [81] These various analyses are applied to sample HRV signals 
from N, DM, CHD, and CHDD patients as displayed in Figure 4.1, Figure 4.2, Figure 
4.3, and Figure 4.4, respectively. For each data set, the trend (information less than 
0.02 Hz) has been removed, and thus, the signals vary about the x-axis. In order to 
visually compare the data sets, the same y-axis units and scale are used. 
119 
In an initial inspection, it is noted that the N patient has the widest HRV range, spanning 
from -100 to 100 ms. The DM and CHDD patient HRV signals display reduced HRV 
range, which in all likelihood, is due to the presence of DAN. Although the CHD patient 
has a wide HRV range that approaches the N patient range, it is obvious that higher 
frequencies are missing from the signal. Each of these initial observations corresponds 
to the HRV diagnoses discussed in Chapter 1. 
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Figure 4.1: Normal (N) HRV signal. 
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Figure 4.2: Diabetic (DM) HRV signal. 
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Figure 4.3: Coronary heart disease (CHD) HRV signal. 
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Figure 4.4: Diabetic coronary heart disease (CHDD) HRV signal. 
4.2.1. Standard Deviation of Normal-to-Normal (SDNN) 
250 300 
250 300 
The standard deviation of the 30 minute HRV gives an index to the overall variability of 
the signal, regardless of the patient's actions. 'Normal-to-Nom1al' refers the requirement 
of having the HRV signal computed from normal QRS complexes within the ECG 
signal, with ectopic and missing beats accounted for and corrected. 
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Since the signal average is known to be zero, then the modified sample STD is defined 
in Equation 4.1, which provides a measure of the data's variability. Specifically, with 
the mean HRV being zero, then 66% of the HRV signal samples are within ±O"x, the 
sample STD. 
1 ~ 2 'f 0 0" = - L....;x. 1 X = 
x N i=l 1 
Equation 4.1: Sample STD, given the sample mean is zero and N is the total number of samples. 
The SDNN is computed for the four sample HRV signals and displayed in Figure 4.5. 
As expected from the initial inspection, the SDNN of the N patient has the largest 
SDNN result since the N patient's HR has the greatest amount of variability. Similarly, 
as expected, the diabetic patients (DM and CHDD) score lower SDNN results, likely 
due to the presence of DAN. 
Normal DM CHD CHDD 
(msec) (msec) (msec) (msec) 
SDNN 86 18 36 17 
Figure 4.5: Standard deviation results for 3D-minute HRV signals ofN, DM, CHD, and CHDD patients. 
4.2.2. Mean of the Standard Deviation of Normal-to-Normal (SDNNIDX) 
The mean of the STD of normal-to-normal (SDNNIDX) is computed as the sample 
mean of the SDNN of each 5 minute intervals. Specifically, the SDNN is computed for 
each of the patient actions during the clinical procedure, according to Equation 4.1. 
Then, the sample mean is computed of from each 5-minute SDNN result for the patient. 
Therefore, this analysis quantifies the variability within each of the patient actions. 
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The SDNN is computed for each of the sample patient HRV signals and is displayed 
graphically in Figure 4.6 and numerically in Figure 4.7. The SDNNIDX is then 
computed as the average of the SDNN for each action, as is also shown in Figure 4.7. 
As expected, the SDNNIDX results are very similar to the SDNN results, with the N 
patient giving the largest value and the diabetic patients (DM and CHDD) giving the 
lowest values due to the likely presence of DAN. 
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Figure 4.6: SDNN for various patients and required actions. 
Normal DM CHD CHDD 
Action (msec) (msec) (msec) (msec) 
Supine 36 28 35 4 
Standing 95 21 34 10 
Sitting 90 10 30 16 
Sitting 9 118 20 30 13 
Sitting 12 76 8 39 20 
Sitting 15 80 13 52 27 
SDNNIDX 82 17 37 15 
Figure 4.7: Sample mean of 5 minute SDNN. 
123 
4.2.3. Standard Deviation of the Mean of Normal-to-Normal (SDANN) 
SDANN is the STD of the 5 minute interval sample means. In other words, instead of 
computing the mean of the 5 minute STD, the STD of the 5 minute means is computed. 
Considering that sample mean is a linear operation, it is expected that SDANN results 
correlate strongly with the SDNNIDX results. 
In order to compute the SDANN, the trend is not removed from the sample HRV 
signals. First, 5 minute sample averages are computed for each of the patient actions, 
and then, the STD is computed from the interval averages, per the results in Figure 4.8. 
As expected, the N patient again scores the highest value, with the diabetic patients 
scoring the lowest. 
Action Normal DM CHD CHDD 
Average Average Average Average 
(msec) (msec) (msec) (msec) 
Supine 525 491 890 547 
Standing 592 484 807 527 
Sitting 580 465 869 550 
Sitting 9 619 477 853 556 
Sitting 12 563 465 853 555 
Sitting 15 565 468 846 548 
SDANN 32 11 27 10 
Figure 4.8: Standard deviation of 5 minute HRV averages. 
4.2.4. Histogram Analysis 
A histogram displays the range of data over a set of predetermined bins. For the sample 
HRV signals, the bins are 100 ms wide and span the range -300 ms to 300 ms. The HRV 
signal data, for each patient, is then sorted and filled in the appropriate bin. The chatt in 
Figure 4.9 displays the histogram of HRV signal for the sample N, DM, CHD, and 
CHDD patients. In agreement with earlier observations, the n0l1na1 HRV signal has the 
124 
widest distribution while the diabetic patients have the narrowest distributions with tall 
central tendencies. 
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Figure 4.9: Histogram analysis of the HRV signal for N, DM, CHD, and CHDD patients. 
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The inter-quat1ile range may be used to index the spread of the data in the histogram. 
The inter-quartile range is defined as the difference between the 75% percentile and 
25% percentile of the s0l1ed data, per the discussion in Chapter 1. Using this definition, 
the inter-quartile range of the sample HRV signals (IQRNN) is computed and displayed 
in Figure 4.10. In agreement with our previous results, the IQRNN indicates the normal 
HRV has the greatest range and that the diabetic patients have a much smaller range. 
I Normal DM CHD CHDD J 
IQRNN 111 20 46 14 
Figure 4.10: Inter-quartile range of the HRV signal for N, DM, CHD, and CHDD patients. 
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4.2.5. Root Mean Square Successive Difference (rMSSD) 
The successive difference estimates the sample derivative and indexes the change in the 
HR per cardiac cycle. In order to account for either an increase or decrease in the HR, 
the root-mean-square (RMS) is taken of the successive difference values, in accordance 
with Equation 4.2. Therefore, the rMSSD gives a measure of change in the HR per time. 
It is expected that the N patient exhibits the greatest rMSSD since, physiologically, the 
N patient has the best cardiac system that is able to change the HR quickly in response 
to changes in the cardiac load. 
N-l 
XRMS -& I (X i +1 - x} 
i=l 
Equation 4.2: Root-mean-squared value of the successive hemi period differences. 
The rMSSD is computed for each of the sample HRV patients and displayed in Figure 
4.11. As expected, the N patient rMSSD result was much greater than that for the 
diseased patients, where the effect is due to the presence of CHD or DM. 
I rMSSD [No~~al [ ~~ [C~D E CH~D J 
Figure 4.11: rMSSD for 3D-minute HRV signals ofN, DM, CHD, and CHDD patients. 
4.2.6. Zero Crossings (zq 
The number of times a signal crosses the x-axis, or zero crossings (ZC), may be used to 
estimate the higher frequency components of a signal, if that signal's trend has been 
removed. This time-based approximation does not account for changes in the sign of the 
signal's slope that do not cross the x-axis, and so, in no way does it give an exact 
measure of the high frequency components. The Matlab m-file algorithm in Figure 4.12 
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is used to compute the ZC for the sample HRV patients. Note that the algorithm 
assumes that signal's trend was previously removed. 
function ZC ~ ZeroCount(R) 
ZC = 0; 
8 = (R(I) > 0); 
LR ~ length(R); 
for i = 2:LR 
82 = (R(i) > 0); 
if (8 -= 82) 
S = 82; 
ZC = ZC + 1; 
end; 
end; 
Figure 4.12: Algorithm to determine the number of zero crossings of a data set. 
The ZC results may be viewed in Figure 4.13. In keeping with initial observations, the 
ZC results indicate that the CHD patient has reduced higher frequency components in 
comparison to the N and diabetic patients. 
Action Normal DM CHD CHDD 
Supine 257 284 78 225 
Standing 277 289 56 318 
Sitting 249 162 87 215 
Sitting 9 299 244 72 207 
Sitting 12 237 159 70 204 
Sitting 15 242 206 52 216 
Average ZC 260 224 69 231 
Figure 4.13: Average zero count results for N, OM, CHO, and CHOO patients. 
4.2.7. Lorenz Plots 
Lorenz Plots, also tem1ed Poincare Plots, display changes per sample by chatiing 
successive samples, xCi) by x(i+ 1), for all X in the sample set. Similar to the rMSSD, 
the Lorenz Plot highlights the changes in HR per cardiac cycle. However, unlike the 
rMSSD, the Lorenz Plots displays both increases and decreases in HR. The changes in 
the HR per cardiac cycle are reflected in the Lorenz Plot as deviations along the 
negative xy-axis of Figure 4.14. The overall range of the HRV signal is reflected in the 
Lorenz Plot as deviations along the positive xy-axis, also shown in Figure 4.14. 
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Figure 4.14: Lorenz Plot dynamics and interpretation. 
The Lorenz Plots of N, DM, CHD, and CHDD patients are displayed in Figure 4.15, 
Figure 4.16, Figure 4.17, and Figure 4.18 respectively. In comparing the plots to 
previous results, the nonnal patient displays the greatest sample range and change per 
cardiac cycle. Similarly, the diabetic patients display reduced range and the CHD 
patient displays reduced changes per cardiac cycle. 
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Figure 4.15: Lorenz Plot of a sample normal patient. 
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Figure 4.16: Lorenz Plot of a sample DM patient. 
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Figure 4.17: Lorenz Plot of a sample CHD patient. 
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CHDD Lorenz Plot 
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Figure 4. I 8: Lorenz Plot of a sample CHDD patient. 
The Lorenz Plots do well in displaying the HRV range and changes per cardiac cycle, 
and provide a means for quick clinical assessment. Even so, other time based analysis 
tools, such as SDNN and rMSSD, better quantify the HRV signal numerically. 
Therefore, though the Lorenz Plot may be used for an immediate visual assessment of 
the HRV signal, it is not pursued further as a basis for patient classification. 
4.2.8. Inter-Breath Pattern Analysis 
It has been shown that HR varies in relation to the respiration. Specifically, normal HR 
decreases between maximum inhalations in response to baroreflex receptors. [82] 
Therefore, inter-breath pattern analysis was developed and applied to the sample 
patients in order to assess its use as a basis for classification. 
The analysis is perfol1ned according to the algorithm in Figure 4.19. Specifically, the 
peak detection algorithm is used to deternline the time index of the maximum 
inhalations. Then the corresponding EeG signal is used to deternline the HRV signal. In 
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accordance with the HRV processing discussion of Chapter 3, the signal is QRS 
complexes of ECG are detected and ectopic beats are removed. 
Detect Respiration Peaks (Maximum Inhalations) 
Determine Inter-Breath HRV Signal 
Normalise HRV Signal 
Stretch Time Index to Standard Interval 
I 
Determine Average Inter-Breath HRV patt~lTII 
Figure 4.19: Algorithm to determine the HRV pattern between maximum inhalations. 
In order to compare the change in the HR between multiple maximum inhalations, the 
HRV signal is normalised and stretched to a standardised time interval. Lastly, the 
average pattem is detelmined from 5 minute individual HRV pattems. The average 
pattem and STD from the average are plotted in Figure 4.20. 
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Figure 4.20: Normalised, average HRV signal between maximum inhalations. 
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The average HRV pattern displayed in Figure 4.20 follows the expectation in that the 
HR decreased between maximum inhalations. However, the STD of all the inter-breath 
HRV patterns implies a high measurement enor in the average HRV pattern. 
Measurement enor may be estimated by the STD divided by the average, per Equation 
4.3. From the chaIt in Figure 4.20, though the average value changes, the STD is 
approximately 0.35 for each value. In accordance with Equation 4.3, the best 
approximate error would result from the greatest measurement. Using 0.65, the best 
approximate error is 54%, which is unacceptably high. 
A . 0' pproxlmate Enor = -
J.l 
~ 035 
HRV Pattern Error = --' - == 0.54 = 54% 
~ 0.65 
Equation 4.3: Estimate of measurement error and application to HRV pattern analysis. 
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The inter-breath HRV pattern analysis was applied to other norn1al and diabetic 
patients. Similar results to that of Figure 4.20 were obtained. Also, similar high 
measurement enor was recorded which implies the analysis is not sufficient as a basis 
for classification. 
4.2.9. Time Based Feature Comparisons 
The time domain based features are compared, excluding the Lorenz Plots and inter-
breath HRV pattern analysis. Specifically, each of the features is applied to sample N, 
DM, CHD, and CHDD patients and then norn1alised, as displayed in Figure 4.21 and 
Figure 4.22. Upon initial inspection, each of the analyses scored highest for the normal 
patient and significantly less for the diseased patients. 
Action Normal DM CHD CHDD 
SDNN 1.00 0.02 0.28 0.00 
SDANN 1.00 0.02 0.79 0.00 
SDNNIDX 1.00 0.02 0.32 0.00 
IRQNN 1.00 0.06 0.33 0.00 
RMSSD 1.00 0.11 0.00 0.06 
ZC 1.00 0.81 0.00 0.85 
Figure 4.21: Normalised, time-based feature results. 
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Figure 4.22: Graphical display of normalized, time-based feature results 
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The nOlmalised feature results are then correlated against one another in order to 
detem1ine dependency. The correlation coefficient is computed according to Equation 
4.4 and provides a measure of dependency between two data sets. A coefficient close to 
one indicates a close relationship between two data sets, and, therefore, dependency. As 
the coefficient becomes less than 1, a more distant relationship between the two data 
sets. 
- ----------------------------------
-k i (Xi - -;,XYi - y) 
i=1 P Xy = ----'=''-----------
CJxCJ y 
Equation 4.4: Correlation coefficient between arrays X and Y. 
Dependent features provide redundant infOlmation to the classifier, and thus, do not 
improve classification. Independent features provide additional information, and thus, 
allow for better classification of the patient condition. The correlation coefficient 
between each ofthe time-based features is computed and displayed in Figure 4.23. 
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SDNN SDANN SDNNIDX IRQNN rMSSD 
SDANN 0.87 
SDNNIDX 1.00 0.89 
IRQNN 1.00 0.89 1.00 
rMSSD 0.94 0.64 0.92 0.92 
ZC 0.24 0.27 0.20 0.20 0.57 
Figure 4.23: Correlation coefficient between each time-based feature. 
As expected, the STD features (SDNN, SDANN, and SDNNIDX) and inter-quatiile 
range (IRQNN) are highly correlated as each gives a similar measure of the HRV. The 
change in HR per cardiac cycle (rMSSD) also displays some dependency with these 
features. However, the ZC feature displays marked independence from the rest of the 
features, and thus, additional information for better classification. 
4.3. Frequency Domain Analysis 
Frequency domain analysis of the HRV signal includes analysis of total signal power 
and comparisons between the signal power of various frequency bands. [83] [84] [85] 
[86] These various analysis procedures are applied to sample HRV signals from N, DM, 
CHD, and CHDD patients displayed in Figure 4.1, Figure 4.2, Figure 4.3, and Figure 
4.4, respectively. 
4.3.1. FFT-Based PSD Estimation 
The PSD is estimated using the Fourier transfOlID. Before computing the transfOlID, the 
HR V signals are filtered using a Hamming window in order to limit the signal 
bandwidth and reduce spectral leakage, which leads to the rise of side-lobes and 
aliasing, as discussed in Chapter 1. The PSD estimate is computed according to 
Equation 4.5, according to the Welch periodogram, where Xi is the HRV signal sample, 
N is the number of samples, and Fs is sampling frequency. In order to quickly estimate 
the PSD, the fast Fourier transform (FFT) is used, which is represented as X(f) 111 
Equation 4.5. [87] 
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P(f) Fs 1_1 I:X.e _i2<;¥.'s 
N Fs ;=0 I 
= Fs IX(ff 
N 
Equation 4.5: FFT based PSD estimation. 
The FFT is used to estimate the PSD for each of the patients. The frequencies of 
interest, 0.04 to 0.40 Hz, are displayed in Figure 4.24. Although the chart is somewhat 
difficult to read, it is observed that the nOlTIlal patient exhibits the greatest power in the 
frequencies of interest. Furthermore, the CHD patient exhibits a reduction for 
frequencies near 0.2 Hz and 0.4 Hz 
PSD - FFT Estimate 
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Figure 4.24: FFT estimate of the PSD for N, DM, CHD, and CHDD patients. The N PSD has the greatest 
magnitude while the CHD displays a peak near 0.3 Hz. 
4.3.2. Autoregressive Based PSD Estimation 
The PSD may also be estimated using an autoregressive (AR) model of the time-based 
signal. The AR coefficients, ai, and number of coefficients (order), p, are chosen to best 
model the time-based signal, X, as shown by Equation 4.6. Once the AR coefficients are 
l36 
detennined, the PSD is estimated according to Equation 4.7. Although the AR-based 
PSD estimation involves the complexity of first determining the AR coefficients, the 
PSD has the advantage of a smoother PSD with sharper spectral peaks. 
I X(k)~-ta;X(H) ·1 
Equation 4.6: AR model, order p, of signal X. 
P(f)= ,,2 
p 
Fs/l + L:>iZ-i i=l 
h 
i2Rfl 
were, z = e IFs 
Equation 4.7: AR-based PSD estimation, where ,,2 represents the variance of the process. 
There are many different algorithms uses to detennine the AR coefficients. The sample 
HRV signals are modelled using the Burg maximal entropy method. [88] The AR 
coefficients are then used to estimate the PSD of each sample patient, which is charted 
in Figure 4.25. Although the AR-based PSD estimate is smoother than the FFT-based 
PSD estimate, the average spectrum of each patient is similar. Specifically, the N patient 
exhibits the greatest amount of power and the CHD patient exhibits a reduction for 
frequencies near 0.2 Hz and 0.4 Hz. 
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Figure 4.25: AR estimate of the PSD for N, DM, CHD, and CHDD patients. 
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Once the PSD is estimated, spectral features are determined in order to characterize the 
HRV signals. Specifically, the total spech'al power and the ratio between the HRV high 
frequency (HF) band and HRV low frequency (LF) band are commonly used as a 
classification basis. [89] LF is defined as the frequency band from 0.05 to 0.15 Hz and 
HF is defined as the frequency band from 0.l5 to 0.5 Hz, as per the discussions in 
Chapter 1. The total PSD and LF IHF ratio is computed for each for each of the sample 
patients and nOffilalised for comparison. The results are displayed in Figure 4.26. 
PSD-FFT PSD -AR LF/HF-FFT LF/HF-AR 
N 1.00 1.00 0.00 0.00 
DM 0.00 0.00 0.03 0.00 
CHD 0.25 0.37 1.00 l.00 
CHDD 0.01 0.03 0.11 0.06 
Figure 4.26: Normalised, frequency-based feature results. 
As an initial inspection, it is observed that the nOlmal patient had the greatest total 
spectral power in the 0.05 to 0.50 Hz frequency band. Also, the CHD patient had the 
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greatest difference between the spectral power in the LF and HF frequency bands. These 
results are con-elated against the SDNN and ZC time-based features and shown in 
Figure 4.27. As expected, the FFT and AR estimates of the total PSD and LF/HF ratios 
are highly con-elated, since both seek to estimate the same values. Also, the PSD feature 
is highly con-elated with the SDNN. This is also expected since, theoretically, the 
variance of a signal gives the same result as the total spectral power of a signal. Lastly, 
since the ZC estimates the fundamental frequency of a signal, it con-elates well with the 
LF/HF ratio frequency since the higher frequency and ratio are both lower for the CHD 
patient. 
SDNN ZC PSD -FFT PSD -AR LF/HF-FFT 
PSD-FFT 1.00 0.27 
PSD-AR 1.00 0.15 0.99 
LF/HF- FFT 0.l3 0.99 0.16 0.04 
LF/HF-AR 0.10 0.99 0.12 0.00 1.00 
Figure 4.27: Correlation coefficient between each frequency-based feature. 
4.4. Time-Frequency Analysis 
As discussed in the introduction of Chapter 1, the HRV signal is time-varying. In other 
words, as time passes, the signal varies in its shape and spectral power. In regards to the 
clinical procedure the patient is required to perform a different action every 5 minutes. 
These actions give rise to different responses for each of the patient types: N, DM, 
CHD, and CHDD. Therefore, it is advantageous to characterise the HRV signal for each 
5 minute interval in order to account for the HRV response to the actions. Therefore, 
time-frequency analysis is required, such as the shOli-tem1 Fourier transform (STFT) or 
wavelet transfOlm (WT). 
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4.4.1. Short-Term Fourier Transform Analysis 
The STFT is used to compute the PSD for each 5 minute interval. The AR-based PSD 
estimate, per Equation 4.6, gives a similar result to the FFT -based estimate and provides 
a smoother PSD with sharper spectral peaks. The sample normal patient HRV signal is 
used and the PSD by time is displayed in Figure 4.28. Note that the PSD changes over 
time in response to patients actions. 
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Figure 4.28: STFT ofa normal patient using the AR estimate of the PSD. 
In order to create a basis for classification, the total PSD is computed as well as the 
power in the LF and HF bands. Lastly, the LF/HF ratio is computed for each 5 minute 
action. As a matter of example, these features are computed for a sample normal patient 
and displayed in the table of Figure 4.29. Of pat1icular interest is the change in the 
LF/HF ratio from supine to patient activity. 
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0-5 5-10 10 -15 15 - 20 20 -25 25 -30 
(min) (min) (min) (min) (min) (min) 
lTotal PSD 97149 68650 37952 68290 106110 56341 
LF 26941 57014 31148 32095 77430 41176 
HF 57556 10522 6328 22627 26980 14163 
~F/HF 0.468 5.419 4.922 1.419 2.870 2.907 
Figure 4.29: AR-estimated PSD, LF, HF, and LF/HF ratio for each HRV action interval. 
4.4.2. Wavelet Transform Analysis 
Similar to the STFT, the WT provides both frequency and time information from the 
HRV signal. Specifically, the HRV signal is decomposed using the Dabachies, 12th 
order, wavelet, which is displayed in Figure 4.30. Previous research has shown that this 
wavelet highlight changes in the HRV signal due to the presence ofDM and CHD. [90] 
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Figure 4.30: Dabachies, lih order scaling function and wavelet. 
Per the discussions in Chapter 1, the wavelet is implemented through the means of 
mirrored quadrature, low pass and high pass filters, as shown previously in Figure 3.22. 
The specific filter coefficients for the Dabachies, 1ih order, wavelet are displayed in 
Figure 4.31. 
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Figure 4.3 I: Dabachies, Iih order wavelet decomposition implementation via low and high pass filters. 
Since wavelet analysis provides multi-resolution time and frequency estimates of the 
PSD, each detail must be interpolated in order to plot the scaled details together on the 
same axes, as is shown in Figure 4.32. Note that the detail scales conespond to ranges 
of frequencies. In accordance with the application of the filter, the following detail 
coefficients represent the following frequency ranges: detail 3 represents the frequency 
range 0.31 to 0.63 Hz, detail 4 represents the frequency range 0.16 to 0.31 Hz, detail 5 
represents the frequency range 0.08 to 0.16 Hz, and detail 6 represents the frequency 
range 0.04 to 0.08 Hz. Note that these bands do not exactly align with the STFT since 
the wavelet employs power of 2 resolutions. 
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Figure 4.32: Decomposition of a sample normal HRV signal using al2'h order, Dabachies wavelet. The 
RMS values of the wavelet coefficients are displayed. 
Once the HRV signal is decomposed over time and frequency, the RMS values of the 
wavelet coefficients [91] are computed in order to compare the signal strength of each 
detail. Then, the sample mean of a pat1icular time interval for each detail is computed in 
order to determine a basis for characterising the signal. Since the patient is requested to 
perform a different action every 5 minutes, the averaging time interval of the wavelet 
coefficients is chosen to be 5 minutes. 
Mathematically, the sample mean of individual RMS values cOlTelates well to the 
sample STD of a particular time interval, per Equation 4.8. The two values are not the 
same since the sum of the absolute value does not equal the root of the sum of squares. 
However, each gives a comparable result and so is highly cOlTelated. Considering the 
outlier discussions of Chapter 2, these methods of estimating the signal strength in each 
detail are very susceptible to the influence of outlying values since all the wavelet 
coefficients of the detail are used in the computation. Therefore, the author proposes the 
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use of the inter-quartile range to estimate the signal strength over each time interval of 
each detail level. As previously mentioned, the inter-qual1ile range estimates the sample 
deviation, and thus the signal power, without being affected by outlying samples. Thus, 
the inter-qual1ile range gives a more robust estimate of the signal power. 
M-I ~ M-I 
W",\lS =~ L\j(w} = ~ Llwil 
i=l i=l 
M-I 
<J w = ~ ~ t;(w} 
Equation 4.8: Comparison of the RMS sample mean and the sample STD over the time interval, M. 
The inter-quartile range is computed for 5 minute intervals for the last six detail levels 
and displayed in Figure 4.33. These range-based features compare well with the 
graphical wavelet decomposition of Figure 4.32. Detail level 2 has the smallest range 
values, which is also true for the graphical decomposition. Furthem10re, both the table 
and the chart display similar time characteristics in detail level 6. Specifically, the detail 
peaks during the middle fifteen minutes of the 30 minute patient screening. Similar to 
other analyses, the diseased patients displayed different HRV signal characterisations 
than the nom1al patients. 
0-5 5 -10 10 -15 15-20 20 -25 25-30 
(min) (min) (min) (min) (min) (min) 
102 (0.63 - 1.25 Hz) 5.03 5.28 4.89 4.74 5.01 4.71 
103 (0.31 - 0.63 Hz) 13.98 14.09 11.50 15.83 17.71 16.89 
104 (0.16 - 0.31 Hz) 57.74 60.37 58.71 48.33 39.54 33.42 
105 (0.08 - 0.16 Hz) 53.01 39.31 35.60 51.43 53.78 35.11 
106 (0.04 - 0.08 Hz) 15.80 77.12 55.50 74.52 20.92 26.08 
Figure 4.33: Inter-quartile range of 5 minute time intervals for each detail level of interest. 
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4.5. Summary 
In order to research the effectiveness of screening patients for DM and CHD, various 
features are computed in order to characterise the HRV signal and detem1ine a basis for 
patient classification, and thus diagnostic of the probable patient condition. The features 
may be time based, frequency based, or time-frequency based. The best feature to use is 
the one that gives the best classification. 
The time based features are highly correlated and tend to give redundant information. 
The frequency based features give insight to the signal spectrum, but lose the time 
infOlmation of specific events such as the patient actions. Time-frequency based 
features, such as the STFT and WT, give insight to the signal spectrum and preserve the 
time of specific events. 
It is common to use the magnitude of the WT coefficients as a measure of the signal 
power at each detail level. However, outlying samples can greatly affect the estimation 
of the average signal power over a celtain time interval. The range also estimates the 
signal power over a certain time interval, but is not as susceptible to the effects of 
outlying samples. 
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Chapter 5 - Arterial Blood Pressure Processing 
5.1. Introduction 
As the HR varies in time, so does the ABP. Therefore, the ABP also gives information 
of the cardiac control systems and is an indicator of DM and CHD. Specifically, a drop 
in ABP is sensed by the baroreceptor, which triggers an increase in the HR, as per the 
discussions of Chapter 1. With an increase in the HR, the ABP then increases. This then 
mediates a decrease in HR. In other words, the HRV and variations in the ABP are 
highly correlated in nonnal patients and may provide additional infom1ation to better 
screen between normal and diseased patients. 
As per the discussions in Chapter 2, the ABP signal is acquired non-invasively from the 
patient's finger. Similar to the HRV analyses, various characteristics are extracted from 
the ABP signal. Specifically, the individual cardiac cycles are detected and the mean-
average, systolic, and diastolic pressures are detem1ined. Also, the cyclic maximum 
change in pressure and the onset of systole is correlated to the ECG signal in order to 
provide additional insight to the patient cardiac condition. As with the HR, these ABP 
characteristics are interpolated to equal spacing in time for use with time based, 
frequency based, and time-frequency based analyses, as per the algorithm in Figure 5.1. 
~-i\1i~ute Strip of Arterial Blood Pressure ~:t~~ 
Maximum Slope Detection 
Determination of Systolic and Diastolic Pressure 
Interpolation to Equally Spaced Data J 
Figure 5.1: Algorithm to extract pressure characteristics from ABP. 
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5.2. ABP Characteristics 
Similar to BeG processing, the general characteristics of the ABP signal are 
investigated in order to make use of a priori information. This knowledge enables the 
design of a robust algorithm with better detection of the signal characteristics. 
The ABP signal is considered to be wide-sense stationary since the peak events occur in 
regular intervals and, although there may be time dependant wavelets within the signal, 
especially during diastole, as a whole, the signal is time-invariant. The ABP signal 
characteristics are displayed in Figure 5.2. Systole refers to the cardiac contraction and 
the systolic pressure is the peak pressure in the cycle. Similarly, the diastole is the 
cardiac rest interval and the diastolic pressure is the lowest pressure reached before 
systole. The maximum slope of the ABP signal has units of change in pressure (mmHg) 
per time and has been shown to correlate well with the cardiac contractility. The dicrotic 
notch, also displayed in Figure 5.2, is due to contraction of the aorta. Specifically, the 
aorta perfOlIDs as a passive pump as it stretches during cardiac systole and then 
contracts during cardiac diastole, causing a small increase in ABP. In recent years, the 
slope of the ABP diastole and dicrotic notch are being investigated as indices to the 
cardiac condition and the compliance of the aorta and arteries. 
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Figure 5.2: ABP signal characteristics. 
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5.3. Detection of ABP Characteristics 
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The ABP signal is acquired from the Ohmeda Finapres 2300 clinical device and a few 
ABP cycles are displayed in Figure 5.3. For non-diseased ABP, the systolic pressure is 
approximately 120 mmHg and the difference between the systolic pressure and diastolic 
pressure is approximately 35 mmHg. In the figure, the systolic pressure is less than 
120 mmHg and the range is approximately 40 mmHg, which are within the normal ABP 
parameters. 
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Figure 5.3: Normal ABP acquired from Ohmeda Finapres 2300. 
Upon further inspection of the normal ABP signal in Figure 5.3, noise is seen in the 
diastole of the cardiac cycle. This noise and the dicrotic notch often hinder peak 
detection of the systolic and diastolic pressure. Therefore, in order to improve peak 
detection, linear FIR, low pass filtering is applied in order to remove frequencies above 
200 Hz, which has been shown not to contain ABP infoffilation. The result of the 
filtering and removal of the noise are shown in Figure 5.4. The reduction in noise is 
readily apparent, and the systolic and diastolic pressure values are unchanged, and thus, 
the ABP information has been preserved. Furthermore, since linear phase filtering is 
used, the relative time infoffilation is unaffected. 
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Figure 5.4: FIR filtered ABP. 
In order to avoid falsely detecting the dicrotic notch as systolic pressure, peak detection 
with refractory is employed. As previously discussed in Chapter 3, the refractory is a 
blanking time in which detection is prevented. Since the ABP signal is from a human, it 
is expected that the maximum expected heart rate is 150 BPM. Therefore, a refractory 
of 400 msec may be used to safely avoid the secondary peak of the dicrotic notch. 
Considering a priori human physiology, the dicrotic notch always follows the systolic 
pressure and occurs during diastole. However, after the detection of the diastolic 
pressure, no refractory is required since the systolic pressure follows immediately. With 
this a priori information of the ABP characteristics, the peak detection with refractOlY 
algorithm of Chapter 3 is again modified for use with detection of ABP features, as seen 
in Figure 3.ll. Using the peak and trough definitions of Chapter 3, the algorithm 
alternately searches for peaks (systolic pressure) and troughs (diastolic pressure) that are 
o greater or 0 less than the neighbouring data. The algorithm in Figure 3.11, is 
implemented as a Matlab m-file and the 0 threshold value is input as 'E'. 'Q' is the data 
being searched and 'R' is the refractory input with units of sample number. 
150 
function [P,T) = ABPPTRDetect(Q, E, R) 
P = [); T = [); a = 1; b = 1; 
Rt -R+l; 
i = 0; d = 0; 
QL = length (Q) ; 
while (i -= QL) 
i=i+l; 
if (d == 0) 
if (Q(a) >= (Q(i) + E)) 
d = 2; 
elseif (Q(i) >= (Q(b) + E)) 
d = 1; 
end; 
if (Q(a) <= Q(i)) 
a = ii 
elseif (Q(i) <= Q(b)) 
b = i; 
end; 
elseif (d==l) 
if (Q(a) <= Q(i)) 
a = i; 
elseif (Q(a) >= (Q(i) + E)) 
P = [P a); 
b = i; d = 2; 
end; 
elseif (d==2) 
if (Q(i) <= Q(b)) 
b = i; 
elseif (Q(i) >= (Q(b) + E)) 
if (b > Rt+R) 
T = [T b); Rt = b; 
end; 
a = i; d 1; 
end; 
end; 
end; 
Figure 5.5: ABP systolic and diastolic detection algorithm with diastole refractory. 
Since the ABP signal is sampled at 500 Hz, a 400 ms refractory is computed to be 200 
samples, per Equation 5.1. 
( samPles)( {sec) Refractory = 500 400msec = 200 Samples sec 1 OOOm sec 
Equation 5.1: Computation of sample refractory based upon human physiology. 
5.3.1. Alternative Algorithm 
By experience, it was found that a slower HR often allows for misdetection of the 
dicrotic notch as systolic pressure. In order to avoid the misdetection, the refractOlY 
input value required continual adjustment. Therefore, an alternative systolic and 
diastolic pressure detection algorithm was developed in order to avoid the dicrotic notch 
with improved robustness. This new algorithm was based on searching for the first 
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derivative of the ABP signal. Specifically, the ABP derivative was estimated using the 
5-point secant estimator of Chapter 3 and displayed in Figure 5.6. Then, the ABP 
derivative peaks are detected, which correspond to the maximum slope of the ABP 
signal. In accordance with human physiology, this maximum slope occurs during 
cardiac systole with the diastolic pressure and systolic pressure occurring before and 
after, respectively, per Figure 5.2. Therefore, once the maximum slope is detected, the 
algorithm searches forward for the systolic pressure peak and backwards for the 
diastolic pressure peak. Specifically, the algorithm searches for the values near zero 
which indicate a peak or trough, per the Matlab m-file in Figure 5.7. 
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Figure 5.6: ABP derivative estimated by a 5-point secant. 
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Note that the algorithm in Figure 5.7 returns the indices of the maximum slope, peak, 
and trough for each cycle, which corresponds to the ABP maximum change in pressure, 
systolic pressure, and diastolic pressure. The algorithm input is the ABP data set and the 
D threshold, which defines a peak. Similar to the discussions of derivate estimation in 
Chapter 3, the ABP derivate is estimated by a 5-point secant in order to reduce higher 
frequency noise. The D threshold is used to define a peak in the ABP. Considering 
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human ABP, an appropriate 0 threshold value is 10 mmHg. The algorithm of Figure 5.7 
uses the 0 threshold value to define both a peak in the ABP and the derivative of the 
ABP. Experimentally, it was detemlined that the ABP derivate is approximately one 
hundred times greater than the ABP values. Using this information and the fact the 
sampling frequency is 500 Hz, the 5-point secant is detemlined with a rate of 
100 (1/500) or 0.2 seconds. 
function [S,P,T] SPTDetect(Q, E) 
% SECANT WITH 0.2 IN ORDER TO USE SAME E 
x = secant(Q, 0.2); 
S = []; P = []; T = []; a = 1; b = 1; i = 0; d 0; 
xL = length (x) ; 
while (i -= xL) 
i = i + 1; 
if (d == 0) 
if (x(a) >= (x(i) + E)) 
d = 2; 
elseif (x(i) >= (x(b) + E)) 
d = 1; 
end; 
if (x(a) <=x(i)) 
a = ii 
elseif (x(i) <= x(b)) 
b = i; 
end; 
elseif (d==l) 
if (x(a) <= x(i)) 
a = ii 
elseif (x (a) >= (x(i) + E)) 
S = [S a]; b i; d 2; 
% BEGIN SEARCH FORWARD FOR SYSTOLIC PRESSURE 
f = ai fi = ai 
while (fi < xL) 
if (Q(f) <= Q(fi)) 
f = fi; 
elseif (Q(f) >= (Q(fi) + E)) 
P = [P f]; fi = xL; 
end; 
fi fi + 1; 
end; 
% BEGIN SEARCH BACK FOR DIASTOLIC PRESSURE 
f = ai fi = ai 
vlhi1e (fi > 0) 
if (Q(f) >= Q(fi)) 
f = fi; 
elseif (Q(fi) >= (Q(f) + E)) 
T [Tf];fi=O; 
end; 
fi fi - 1; 
end; 
end; 
elseif (d==2) 
if (x(i) <= x(b)) 
b = i; 
elseif (x(i) >= (x(b) + E)) 
a = i; d = 1; 
end; 
end; 
end; 
Figure 5.7: ABP systolic and diastolic detection algorithm based upon initial maximum slope detection. 
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5.4. ABP Feature Extraction 
The detection algorithm of Figure 5.7 is used on a sample ABP signal. The first 
10 seconds are displayed in Figure 5.8, along with the results of the detection algorithm. 
In particular, the figure displays the ABP signal along with the Ohmeda Finapres 2300 
self-calibration interval, which occurs for a few seconds each minute. Note that the 
systolic, diastolic, and maximum change in pressure are detected without false 
detections during the calibration interval. 
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Figure 5.8: ABP with marked detection points, Note the Ohmeda Finapres calibration interval. 
5.4.1. Maximum Change in Pressure 
It has been shown that the cyclic, maximum change in pressure (~ MAX) of the ABP 
signal is an index to the cardiac contractility, and thus, the cardiac condition. As with 
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the HR, the heat1 contractility responds to changes in the cardiac load. Therefore, ~~ MAX 
is acquired as a possible index for patient classification and assessment of cardiac 
condition. 
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Figure 5.9: ABP cyclic maximum change in pressure over 5 minutes. 
Figure 5.9 displays the ~~ MAX of a nOlmal ABP signal over 5 minutes. As expected, the 
~~ MAX varies with time with an average value of approximately 1100 mmHg/sec and a 
STD of approximately 110mmHg/sec. These values are later assessed as to their 
usefulness in patient screening. 
5.4.2. Diastolic, Mean-Average, and Systolic Pressure 
The mean-average pressure (MAP) is defined in several ways. Some have defined it as 
the average of the systolic and diastolic pressure over one cycle while others define it as 
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the average of all the ABP samples over one cycle. Figure 5.10 displays the cyclic 
diastolic, MAP, and systolic pressure of the ABP signal over a five minute period. 
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Figure 5.10: ABP signal with systolic, mean-average, and diastolic pressure measurements. 
In comparing c;:; MAX and pressure features of Figure 5.9 and Figure 5.10, respectively, it 
is noted that the features correspond well. Specifically, just as ~~ MA,X noticeably 
decreases just after 150 seconds, and thus an implied reducing in cardiac contraction, so 
the diastolic, MAP, and systolic pressures drop. 
5.4.3. QA Interval 
Besides the cyclic, maximum change in pressure of the ABP, it has been shown that the 
cardiac contractility may be indexed by comparing the time interval between the 
Q-point of the QRS complex of the ECG and systole onset. [92] This transit time is 
termed the QA interval and is specifically defined as the time between the Q-point of 
the ECG QRS complex and following diastolic pressure, termed the 'A' point. It has 
been shown that this transit time is an index for cardiac contractility, [93] and thus, a 
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measure of the cardiac condition. Physiologically, this measurement is the transit time 
from depolarisation of the ventricles and initial rise in pressure of the ABP, as shown in 
Figure 5.11. The QA interval measurement relates the electrical and mechanical 
properties of the cardiac system and has been shown to index the cardiac contractility. 
However, others have noted that the transit time is also dependant upon the atierial 
compliance and cardiac load. Even so, since the ECG and ABP are acquired at virtually 
the same time, the QA interval may be computed to a 2 msec resolution, in accordance 
with the sampling period. 
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Figure 5.11: ABP and ECG signals plotted on one chart with QA interval indicated. 
In order to compute the QA interval, the time index of the ECG Q-point must be 
detected. The Q-point is displayed in Figure 3.2 and defined as the onset of the ECG 
QRS complex. Considering the morphology of the QRS complex, the R-wave gives the 
maximum slope and most robust feature for detection, per the discussion of Chapter 3. 
The Q-point is defined as the first positive slope, closest to zero that immediately 
precedes a local maximum slope of the R-wave, as displayed in Figure 5.12. 
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Furthermore, as previously discussed in Chapter 3, the maximum slope of the T-wave 
can approach the value of the R-wave maximum slope, as shown in Figure 5.12. In 
order to avoid this false detection, the refractory is employed to prevent search of a local 
maximum until the T -wave has passed. 
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Figure 5.12: ECG derivative estimated by a 5-point secant, per the discussion in Chapter 3. 
Given the previous Q-point definition and refractory requirement, the Q-point detection 
algorithm of Figure 5.13 was developed. Specifically, the algorithm first estimates the 
derivative of the ECG signal using a 5-point secant. Then the algorithm searches for a 
local maximum, which is defined as a derivative value that is 0 greater than its 
neighbouring samples. This 0 threshold value is input as 'E' to the algorithm. Once a 
local maximum has been detected, the algorithm begins a search back for the first 
derivative value greater than zero, which indicated the onset of the QRS complex. 
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Lastly, a refractory is imposed to prevent possible false T -wave detections before the 
algorithm begins to search for the next local maximum. 
function [p] = QECGDetect(Q, E, R) 
Q = secant(Q, 0.002), 
P = [], a = I, b = I, 
Rp = -R+l, Rt = -R+l, 
i = 0, d = 0, 
QL = length (Q) ; 
while (i -= QL) 
i=i+l; 
if (d == 0) 
if (Q(a) >= (Q(i) + E)) 
d = 2, 
elseif (Q(i) >= (Q(b) + E)) 
d I, 
end, 
if (Q(a) <= Q(i)) 
a ii 
elseif (Q(i) <= Q(b)) 
b i, 
end, 
elseif (d==I) 
if (Q(a) <= Q(i)) 
a = ij 
elseif (Q(a) >= (Q(i) + E)) 
if (a > Rp+R) 
Rp = a, 
% BEGIN SEARCH BACK FOR ECG Q POINT 
f = a, 
while (f > 0) 
if (Q(f) < 0) 
P = [P (f+1)], f 0, 
end, 
f = f - 1, 
end, 
end, 
b i, d 2, 
end, 
elseif (d==2) 
if (Q(i) <= Q(b)) 
b = ij 
elseif (Q(i) >= (Q(b) + E)) 
if (b > Rt+R) 
Rt = b· 
end; 
a = i; d = 1; 
end, 
end; 
end, 
Figure 5.13: ECG Q-point detection algorithm based upon detection ofR-wave slope. 
The Q-point detection algorithm of Figure 5.13 was applied to sample, normal ECG. As 
previously mentioned in Chapter 3, the refractory was set to 200 samples and the 
threshold value was set to 100 m V Is, per inspection of the data. The results for the first 
few QRS complexes are displayed in Figure 5.14, along with the associated Q-point 
detections. Note the conect detections without false, T-wave detections. 
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Figure 5.14: Normal ECG with indicated Q point detection. 
Once the time indices of the ECG Q-points and the time indices diastolic pressure are 
identified, then the QA interval may be computed. Specifically, the algorithm of Figure 
5.15 is used. Since the QA interval is a time measurement, its value must be greater than 
zero. Also, since the QA interval is a measurement of the transit time between the QRS 
complex and pressure increase, it must be less than the period for one cardiac cycle. 
Using the a prior information, the algorithm of Figure 5.15 compares the Q-point time 
indices and diastolic pressure time indices in order to determine reasonable QA interval 
values. Each QA interval calculation is assigned the Q-point time index as a matter of 
convenience and for interpolation to equally spaced data. 
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function [QAj=QADetect(a, q, maxqa) 
N = 1ength(q); M = 1ength(a); QA = [J; i 1; 1; 
if ((N>2) & (M>2)) 
while ((i < N) & (j < M)) 
if ((a(i)-q(j)) <= 0) 
i = i + Ii 
else 
if ((a (i) - q(j)) > maxqa) 
j = j + 1; 
else 
QA= [QA; [q(j) (a(i) - q(j))]]; 
j = j + 1; 
i = i + 1; 
end; 
end; 
end; 
end; 
Figure 5.15: Algorithm to determine QA interval from ABP and ECG. 
The algorithm of Figure 5.15 is applied to the diastolic pressure and Q-point indices of a 
sample, normal patient. The results are displayed in Figure 5.16 over a 5 minute period. 
The average QA interval time is approximately 330 msec with a 12 msec standard 
deviation. 
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Figure 5.16: QA Interval time between ECG Q-point and onset of systole. 
In comparing to the ~~ MAX cardiac contractility index, of Figure 5.9, there is no apparent 
change in the QA interval after the 150 second time index. Furthermore, the two feature 
161 
signal shapes are different, and so, there is little observable correlation between the two 
indexes for cardiac contractility. 
5.5. Summary 
The ABP is processed in order to detelmine the diastolic, mean-average, and systolic 
pressures. Furthem1ore, the maximum change in pressure and cardiac transit time are 
detelmined as possible indices to the cardiac contractility. For robustness and 
minimisation of false detections, linear FIR low pass filtering and detection of the 
maximum pressure slope are used. Also, the a priori information of the ABP signal 
morphology is used in order to best detect the diastolic and systolic pressure, given the 
location of the maximum pressure slope. 
Once processed, these ABP characteristics are analysed by time, frequency, and 
time-frequency based methods in order to detelmine which parameters are best for 
patient screening and classification. 
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Chapter 6 - Classification Results 
6.1. Introduction 
The analyses of HRV and ABP of Chapters 4 and 5 are used as a basis for classification 
and screening of DM and CHD in patients. In order to limit the scope of this initial 
study, the screened patients are limited to males between the ages of 44 and 59 years. 
Within this group, patients are known to be N, DM, CHD, or CHDD, in accordance 
with their medical history and clinical laboratory results. 
The study planned to assess the classification results with at least 50 patients from each 
class (N, DM, CHD, and CHDD), with a total of 200 patients; however clinical 
operations provided complete data on only 17 total patients. Many more patients have 
been tested, however many patients did not have their condition confirmed by 
laboratory testing. Thus, even though the proposed screening process was able to screen 
many patients, most were not included in the testing as their conditions were not 
confinned by traditional laboratory tests. Complete testing of a patient was not only 
tiring but complex, which fmiher highlights the need for new, non-complex clinical 
screening methodologies. Therefore, due to the limited number of patients with known 
conditions, this pilot study focuses on assessment of the proposed screening 
methodology and the analyses which best highlight the differences between the patient 
conditions. 
Figure 6.1 displays the relative HRV signals for the 17 patients. Specifically, five N, 
two CHD, five DM, and five CHDD patients are used for assessment of the 
classification results. Upon visual inspection, it is noted that, in general, the Nand CHD 
patients display a greater range and higher spectral components. 
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Figure 6.1: HRV signal of 17 patients with known conditions. 
The systolic ABP (SABP) and diastolic ABP (DABP) signals for each of the 17 patients 
are displayed in Figure 6.2 and Figure 6.3, respectively. Again, the y-axis of the chalis 
are fixed in order to display relative changes between the patients. Upon visual 
inspection of these SABP signals, there does not appear to be any significant differences 
between the patient classes. Similarly, the DABP signals do not display any significant 
differences between the patient classes. 
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Figure 6.2: Systolic ABP signal of 17 patients with known conditions. 
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Figure 6.3: Diastolic ABP signal of 17 patients with known conditions. 
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6.2. Clinical Screening of DM 
The HRV and ABP analyses tests of Chapters 4 and 5 are used as feature bases for 
classification of DM and non-DM patients. Specifically, a minimum distance classifier 
is built using supervised learning and then applied to each patient. The classification 
results, sensitivity, specificity, positive predictive value, and negative predictive values 
are then determined, per the MatLab m-file of Figure 6.4. 
function [sn, sp, pvp, nvp, class] ~ TestDMAnalyses(features); 
% Test Results 
% sn ~ sensitivity, sp ~ specificity, 
% pvp ~ positive predictive value, nvp negative predictive value 
% USE SUPERVISED LEARNING CLASSIFICATION 
ndm = features(:,1:7); 
dm = features(:,8:17); 
undm ~ mean(ndm')'; 
udm ~ mean(dm')'; 
cndm ~ inv(cov(ndm')); 
cdm ~ inv(cov(dm')); 
% CLASSIFY 
class = zeros(1,17); 
for i=1:17; 
d1 (features (:,i)-undm) '*cndm*(features(:,i)-undm); 
d2 = (features(:,i)-udm) '*cdm*(features(:,i)-udm); 
if (d2 < dl) 
class(i) 1; 
end; 
end; 
a 7 - sum(class(1:7)); 
b sum(class(1:7)); 
c 10 - sum(class(8:17)); 
d sum(class(8:17)); 
sn ~ d/ (c+d) ; 
sp ~ a/ (a+b) ; 
pvp d/ (b+d) ; 
nvp ~ a/ (a+c) ; 
Figure 6.4: MatLab m-fiIe used to test OM classification based upon a particular analysis. 
The classification results are displayed in Figure 6.5. A 'I' indicates positive for the 
presence of DM and, conversely, a '0' indicates non-diabetic. As far as the feature 
analyses, SDSABP refers to the STD of the SABP. Also, note that the 'IDX' features, 
such as SDNNIDX, account for the patient action response since these analyses are 
applied to each 5 minute action interval of the signal. Similarly, the STFT and wavelet 
features also account for the action response as their time infoTIl1ation is divided into 
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5 minute intervals. Lastly, the wavelet details, which reflect various frequency ranges, 
are separated into individual features in order to detemline which details (frequency 
ranges) give the best classification results. 
Non-Diabelic Diabelic 
Feature N N N N N CHD CHD OM OM OM OM OM CHDD CHDD CHDD CHDD CHDD 1 2 3 4 5 1 2 1 2 3 4 5 1 2 3 4 5 
SDNN 0 0 0 1 1 1 0 1 1 1 1 1 0 1 0 0 1 
SDANN 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 0 1 
rMSSD 0 0 0 0 0 0 0 1 1 1 1 1 0 1 0 1 1 
ZC 1 0 0 0 0 0 0 1 1 1 1 0 1 0 1 1 1 
IRQNN 0 0 0 1 1 0 0 1 1 1 1 1 0 1 0 0 1 
PSOHRV 0 0 0 0 0 0 0 1 1 1 1 1 0 1 0 1 1 
LFHRV 0 0 0 0 0 0 0 1 1 1 1 1 0 1 0 1 1 
HFHRV 0 0 0 0 0 0 0 1 1 1 1 1 0 1 0 1 1 
LFHRV/HFHRV 1 0 0 1 1 1 1 1 0 0 1 1 0 1 0 0 1 
dP/dlm" 1 0 0 0 0 0 0 1 0 1 1 0 1 1 1 1 1 
SDSABP 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
QA 0 0 0 1 0 0 1 0 1 1 1 0 1 0 1 1 0 
SDNNIDX 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 ! 
SDSABPIDX 0 0 1 1 1 1 1 0 1 1 0 1 1 0 1 1 1 
PSOSABP 1 0 1 1 1 1 1 1 1 0 1 1 1 1 1 1 1 
LFsABP 1 0 1 0 1 1 1 0 1 1 1 1 1 1 1 1 1 
HFsABP 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 
LFsABp/HFsABP 0 1 0 0 0 1 0 1 0 1 1 1 1 1 1 1 0 
LFsABplLFHRV 1 1 1 1 1 1 0 1 1 1 1 1 0 1 0 1 1 
HFsASp/HFHRV 1 1 1 1 1 0 1 1 1 1 1 1 0 1 0 1 1 
dP/dlm"IDX 1 0 0 1 0 0 0 1 1 1 1 1 1 1 1 1 1 
QAIDX 0 1 0 0 0 0 0 1 0 1 1 1 1 1 1 1 1 
STFTpSD 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 
STFT LFHRV 0 0 0 0 0 0 0 1 0 1 1 1 1 1 1 1 1 
STFT HFHRV 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 
STFT 0 0 0 1 0 0 0 1 1 1 1 1 1 1 1 1 1 LFHRV/HFHRV 
WTHRV 02 0 0 0 0 0 0 0 1 1 0 1 1 1 1 1 1 0 
WTHRV 03 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 
WTHRV 04 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 
WTHRV 05 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 
WTHRV 06 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 
WTHRV 07 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 
WTHRV LF/HF 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Figure 6.5: Classification results ofDM screening: 0 indicates non-DM and a 1 indicates DM. 
The DM classification results of Figure 6.5 are then used to detemline the sensitivity, 
specificity, positive predictive value and negative predictive value in order to assess 
classifier perf01111ance. The analysis that gives the highest probabilities is the best for 
screening DM. 
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The classification results are displayed in Figure 6.6. Note that undefined results are 
displayed with a 'NaN' to signify the result is 'Not a Number', in accordance with 
MatLab convention. 
Feature Sensitivity Specificity +PV -PV 
SDNN 70% 57% 70% 57% 
SDANN 90% 100% 100% 88% 
rMSSD 80% 100% 100% 78% 
ZC 80% 86% 89% 75% 
IRQNN 70% 71% 78% 63% 
PSDHRV 80% 100% 100% 78% 
LFHRV 80% 100% 100% 78% 
HFHRV 80% 100% 100% 78% 
LF HRV/H FHRV 50% 29% 50% 29% 
dP/dlma, 80% 86% 89% 75% 
SDSABP 100% 14% 63% 100% 
QA 60% 71% 75% 56% 
SDNNIOX 100% 100% 100% 100% 
SDSABPIDX 70% 29% 58% 40% 
PSDSABP 90% 14% 60% 50% 
LFsABP 90% 29% 64% 67% 
HFsABP 10% 86% 50% 40% 
L F SABP/H F SABP 80% 71% 80% 71% 
LFsABP/LFHRV 80% 14% 57% 33% 
HFsABP/HFHRV 80% 14% 57% 33% 
dP/dtma,IDX 100% 71% 83% 100% 
QAIDX 90% 86% 90% 86% 
STFTpSD 100% 100% 100% 100% 
STFT LFHRV 90% 100% 100% 88% 
STFT HFHRV 100% 100% 100% 100% 
STFT LFHRV/HFHRV 100% 86% 91% 100% 
WTHRV D2 80% 100% 100% 78% . 
WTHRV 03 100% 100% 100% 100% 
WTHRV 04 100% 100% 100% 100% 
WTHRV 05 100% 100% 100% 100% 
, 
WTHRV D6 100% 100% 100% 100% 
WTHRV 07 100% 100% 100% 100% 
WTHRV LF/HF 0% 100% NaN 41% I 
Figure 6.6: DM screening results for each classifier. 
In reviewing the DM screening results, it is noted that the SDNNIDX, STFTpso, STFT 
HFHRV, and all the WaveletHRv detail features (except level 2) gave the best 
classification results. Theoretically, the PSD of a sample is equivalent to its variance. 
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Thus, it is expected that both the STFT PSD and SDNNIDX give the same results. Also, 
since the STFTpSD gave similar results to the STFT HFHRV, it is noted that the HF range 
(0.15-0.5 Hz frequency band of the HRV signal) gives significant information to 
distinguish between DM and non-DM patients. Lastly, the wavelet based features with 
decomposition levels 3 to 7 performed equally well in distinguishing between DM and 
non-DM patients. 
It is noted that classifier results based upon the ABP signal performed poorly in 
screening for DM. From the introduction, is it known that changes in the HR con-elate 
with changes in the ABP, and therefore, also indicate the presence of DAN. However, 
based upon these results, the ABP does not screen well for DAN, and thus, DM. 
Similarly, although the QAIDX feature gave better results than the QA interval, neither 
produced screening probabilities greater than 90%. This indicates that though QAIDX is 
affected by the presence ofDM, it is not a good indicator of the disease. 
As a summary result, analysis features Figure 6.6 that consider the patient actions out-
perfOtTIl the analyses that do not consider the patient action. In other words, features, 
which consider the time-varying nature of the HRV signal in response to the patient's 
actions, better screen for DM than those features that analyse the 30-minute HRV signal 
as a whole. Figure 6.7 displays the average classifier results for features based upon the 
HRV signal that are independent of the patient actions, such as the SDNN, and those 
that are dependent upon the patient action, such as the SDNNIDX. The ABP based 
features were excluded in order for a better comparison. 
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Sensitivity Specificity +PV -PV 
Features independent of the patient action 79% 88% 91% 75% 
Features considering the patient action 96% 97% 98% 96% 
--
Figure 6.7: Comparison between DM screening classifiers that consider the patient action and those 
independent ofthe patient action. 
6.3. Clinical Screening of CHD 
Similar to DM screening, the HRV and ABP feature analyses of Chapter 4 and 5 are 
used as a basis for classification of CHD and non-CHD patients. Specifically, a 
mlmmum distance classifier is again built using supervised learning of the known 
patient conditions, and then applied to each patient. The classification results are 
compared by detelmining the sensitivity, specificity, positive predictive value, and 
negative predictive values as shown in the MatLab m-file of Figure 6.8. Note that the 
algorithm is very similar to that of Figure 5.7, except that the patient classes are divided 
into CHD and non-CHD patients for the supervised learning. 
function [sn, sp, pvp, nvp, class) = TestCHDAnalyses(features); 
% Test Results 
% sn = sensitivity, sp = specificity 
% pvp = positive predicitive value, nvp negative predicitive value 
% DETERMINE THRESHOLD 
ndm = features(:,[1:5 8:12)); dm = features(:,[6:7 13:17)); 
undm mean(ndm')'; udm = mean(dm')'; 
cndm = inv(cov(ndm')); cdm = inv(cov(dm')); 
% CLASSIFY 
class = zeros(1,17); 
for i=1:17; 
d1 (features(:,i)-undm) '*cndm*(features(:,i)-undm); 
d2 = (features(:,i)-udm) '*cdm*(features(:,i)-udm); 
if (d2 < d1) 
class (i) 1; 
end; 
end; 
a = 10 - sum(class([1:5 8:12))); b sum(class([1:5 8:12))); 
c = 7 - sum(class([6:7 13:17))); d sum(class([6:713:17))); 
sn d/(c+d); sp a/(a+b); pvp d/(b+d); nvp a/(a+c); 
Figure 6.8: MatLab m-file used to test CHD classification based upon a paIiicular analysis. 
The classification results are displayed in Figure 6.9 whereby a '1' indicates the presence 
of CHD in the patient and a '0' indicates no CHD, and thus, a N patient. As with the 
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previous DM screening, these classification results are used to detennine the sensitivity, 
specificity, positive predictive value and negative predictive probabilities which are 
displayed in Figure 6.10. 
Non-CHD CHD 
Feature N N N N N DM DM DM DM DM CHD CHD CHDD CHDD CHDD CHDD CHDD 1 2 3 4 5 1 2 3 4 5 1 2 1 2 3 4 5 
SDNN 1 1 1 0 0 1 0 0 0 1 1 1 1 1 1 1 0 
SDANN 1 1 1 1 1 1 0 0 0 0 1 1 1 1 1 1 0 
rMSSD 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 
ZC 1 0 0 0 0 1 1 1 1 0 0 0 1 0 1 1 1 
IRQNN 1 1 1 1 1 0 0 0 0 1 1 1 1 1 1 1 0 
PSDHRv 0 1 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 
LFHRV 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
HFHRV 1 0 1 1 1 1 1 0 1 1 1 1 0 1 0 0 1 
LFHRV/HFHRV 1 0 0 1 1 1 1 0 1 1 1 1 0 1 0 0 1 
dP/dtm" 1 0 0 0 0 1 0 1 1 0 0 0 1 0 1 1 0 
SDSABP 0 0 0 1 1 0 1 0 0 1 0 1 1 1 1 0 1 
QA 0 0 0 1 0 0 1 1 1 0 1 1 1 1 1 1 0 
SDNNIDX 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
SDSABPIDX 1 0 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 
PSDsABP 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 0 0 
lFsABP 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 
HFsABP 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 
lFsABp/HFsABP 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
LFsABplLFHRV 1 1 1 1 1 1 0 0 1 1 1 1 1 1 1 1 1 
HFsASp/HFHRV 1 1 1 1 1 1 1 0 1 0 1 1 1 1 1 1 1 
dP/dtm"IDX 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 
QAIDX 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 
STFTpSD 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 
STFT LFHRV 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 1 
STFT HFHRv 0 0 0 0 0 0 0 0 0 0 1 1 1 0 1 1 0 
STFT 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 LFHRv/HFHRv 
WTHRV D2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
WTHRV D3 0 0 0 0 0 0 0 0 0 0 1 1 1 0 1 1 0 
WTHRV D4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 
WTHRV D5 0 0 0 0 0 0 0 0 0 0 1 0 1 0 1 1 1 
WTHRV 06 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 0 
WTHRV D7 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 1 0 
WTHRV LF/HF 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Figure 6.9: Classification results of CHD screening: 0 indicates non-CHD and a 1 indicates CHD. 
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Feature Sensitivity Specificity +PV -PV 
SONN 86% 50% 55% 83% 
SOANN 86% 40% 50% 80% 
rMSSO 86% 0% 38% 0% 
ZC 57% 50% 44% 63% 
IRQNN 86% 40% 50% 80% 
PSOHRV 29% 90% 67% 64% 
LFHRV 0% 100% NaN 59% 
HFHRV 57% 20% 33% 40% 
LFHRV/HFHRV 57% 30% 36% 50% 
dP/dtmax 43% 60% 43% 60% 
SOSABP 71% 60% 56% 75% 
QA 86% 60% 60% 86% 
SONNIOX 100% 0% 41% NaN 
SOSABPIOX 100% 20% 47% 100% 
PSOSABP 71% 100% 100% 83% 
LFSABP 14% 100% 100% 63% 
HFsABP 29% 100% 100% 67% 
LFsABP/HFsABP 0% 100% NaN 59% 
LFsABP/LFHRV 100% 20% 47% 100% 
HFsABP/HFHRV 100% 20% 47% 100% 
dP/dtmaxlOX 71% 100% 100% 83% 
QAIOX 86% 0% 38% 0% 
STFTpSD 86% 0% 38% 0% 
STFT LFHRV 86% 0% 38% 0% 
STFT HFHRV 71% 100% 100% 83% 
STFT LFHRV/HFHRV 100% 0% 41% NaN 
WTHRV 02 100% 0% 41% NaN 
WTHRV 03 71% 100% 100% 83% 
WTHRV 04 86% 0% 38% 0% 
WTHRV 05 71% 100% 100% 83% 
WTHRV 06 86% 0% 38% 0% 
WTHRV 07 71% 0% 33% 0% 
WTHRV LF/HF 0% 100% NaN 59% 
Figure 6.10: CHD screening results for each classifier. 
In reviewing the CHD screening results, it is noted that PSDSABP, dP/dtMAxIDX, 
STFT HFHRV, and WaveletHRv decomposition detail level 3 and 5 features give the best 
classification results. The PSDSABP estimates the total SABP power and gives an 
indication of the sum-total change in the SABP over the entire patient screening, 
regardless of the patient actions. This is an unexpected result that may be singular to the 
small number of patients in this study, and requires fmiher investigation. 
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The dP/dtMAXIDX feature is known to index cardiac contractility, which in tum, gives a 
measure of the cardiac condition and strength. Reduced contractility indicates coronary 
difficulty and warrants further testing of the cardiac system, such as angiography. 
Furthermore, this feature is indexed to the patient actions, which provides additional 
information about the response of the patient cardiac system. 
The QA and QAIDX features have been shown to also give a measure of the cardiac 
contractility, as was previously discussed. However, in this study, the QA and QAIDX 
features were found to be poor indicators for screening patients for the presence of 
CHD. 
Lastly, in accordance with the discussions of Chapter 1, the frequency spectrum of the 
HRV signal is affected by the presence of CHD. Specifically, the HF band, whether 
estimated by the STFT or wavelet, displays changes between non-CHD and CHD 
patients, and thus, is a good indicator of the presence of CHD in a patient. It is also 
noted that, similar to the DM screening results, the HRV features which are indexed to 
the patient action better screen for CHD than those features which are based on the 
entire 30-minute HRV signal. 
6.4. Neural Network Screening of DM and CHD 
Per the discussions in Chapter 1, NN based classification has been shown to perform 
better than distance based classification. In this section of the study, three different NN 
classifiers are designed and compared. The first design is based on the SDNNIDX 
feature of the HRV signal and dP/dtM~'(IDX feature of the ABP signal. The second is 
based upon the STFT PSD and HF signals. The last is based upon the WT, detail levels 
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3, 4, and 5. These specific features are chosen as each perfOlwed the best in screening 
for either DM or CHD. 
For each of the NN classifiers, the same NN architecture is used in order to compare the 
influence of the features upon the NN classifiers. The specific NN architecture consists 
of three layers: an input layer, a hidden layer of 20 neurons, and an output layer. The 
output layer has two binary outputs: 0 / I to indicate the presence of DM, and 0 / 1 to 
indicate the presence of CHD. 
In order to test the NN, a leave-one-out analysis is perfomled. In particular, the NN is 
trained using all the known patients, except one. The trained NN is then applied to the 
one remaining patient and the classification result is detennined. This procedure is then 
repeated for each of the 17 patients and the sum total classification results are used to 
determine the sensitivity, specificity, positive predictive value, and negative predictive 
value. Using this procedure, it was found that all three NN classifiers scored 100% for 
the sensitivity, specificity, positive predictive value, and negative predictive value for 
both DM and CHD screening. Thus, this test shows that the NN classifier is quite strong 
and robust, but did not give any comparison between the three NN classifiers based 
upon different features. 
The NN classifiers were tested again using, leave-one-class-out analysis. For this test, 
the NN is trained using all the known patients, except one fi'om each condition class: N, 
DM, CHD, and CHDD. The trained NN is then applied to the four remaining patients 
and the classification results are detennined. This procedure is then repeated several 
times for different members of each condition class and the sum total classification 
results are used to determine the sensitivity, specificity, positive predictive value, and 
negative predictive value. Using this procedure, it was again found that screening for 
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DM scored 100% for the sensitivity, specificity, positive predictive value, and negative 
predictive. However, all three NN classifiers elTed in screening of CHD, as displayed in 
the table of Figure 6.11. 
Features used for NN Classifier Sensitiv~ ~ecific~ +PV -PV 
SONNIOX & dP/dtmaxlOX 81% 97% 95% 88% 
STFTpsD and HF 97% 97% 96% 91% 
WT 03, 04 and 05 97% 97% 96% 91% 
Figure 6.11: Comparison between NN classification results in screening for CHD. 
In reviewing the NN classifier results of Figure 6.11, it is noted that the NN classifier 
based upon the STFT and WT time-frequency analyses performed better than the 
classifier based upon the SDNNIDX and dP/dtmaxIDX features. Thus, the time-
frequency based features, which are indexed to the patient action, provide a better basis 
for classification. 
6.5. Summary 
Without doubt, a clinical screening system based on 17 patients is not statistically 
significant and walTants fmiher testing on additional patients with known DM and CHD 
conditions. Even so, the initial results of this study confirm the necessity of 
classification features based upon time-frequency analysis in order to effectively screen 
for both DM and CHD. These types of analyses decompose the physiological signal 
over a range of frequencies while preserving the time information. That is important in 
order to measure how the spectmm of a signal changes over time, usually in regards to 
an evoked response. 
As far as screening for DM, the requirement of the patient to perfom1 various actions is 
impOliant in effecting a response in the ANS, which controls the HR. This response 
varied between DM and non-DM patients, due to DAN. According to the classification 
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results, the best features are those that measure the variance in the HR per patient 
action, such as the SDNNIDX, STFT, and WT. As for the classification of CHD, the 
best features are those that consider the spectrum of the HRV signal or the maximum 
change in ABP, which gives an indication of cardiac contractility. Additionally, as with 
the DM features, those features that are dependent upon the patient actions, such as the 
dP/dtmaxIDX, STFT, and WT, give better CHD classification results. 
Lastly, based upon the sensitivity, specificity, positive predictive value, and negative 
predictive value, the NN based classifiers performs better than the Euclidean, distance 
based classifiers, using the analysis features. The sensitivity is the probability that a 
diseased patient is correctly classified as having the disease, and the specificity is the 
probability that a disease-free patient is correctly classified as not having the disease. 
The positive predictive value is the probability that a patient actually has the disease 
when the clinic screening indicates the disease is present in a patient. The negative 
predictive value is the probability that a patient actually does not have the disease when 
the clinic screening indicates the disease is not present in a patient. For DM screening, 
each of these probabilities scored 100% for classifiers based upon the SDNNIDX, 
STFT, or WT features. For CHD screening, the probabilities scored less than 100%, but 
well over 90%, indicating the ability of the STFT and WT of the HRV signal to screen 
for CHD. However, as previously mentioned, these results are far from providing 
sufficient statistics and additional patients with known conditions are required to better 
assess the classification performance. 
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Chapter 7 - Conclusions 
7.1. Summary 
A successful clinical screening procedure depends on many factors. Foremost, the 
procedure must be cost effective, reproducible, and have easily interpretable results. 
Additionally, the screening must incorporate a methodology that requires simple 
training of the clinical staff and minimal patient cooperation. Lastly, the procedure must 
be safe and entail no unnecessary risk to the patient. 
The researched clinical screening system employed a low-cost, PC and turnkey DAQ 
system for collecting ECG, respiration, and ABP from the patient. The measurement of 
non-invasive physiological signals minimises the patient risk of infection, requires no 
analgesics, and reduces measurement artefact due to patient stress. The clinical 
methodology required the patient to lie quietly (supine) for 5 minutes while the 
physiological data is collected. Then the patient is request to stand while an additional 5 
minutes of data is collected. Similarly, the patient is requested to sit/squat and breathe at 
3 different rates while the physiological data is again collected, for a sum total of 30 
minutes of physiological DAQ. These actions are required in order to evoke a response 
from the patient's HR control system which is managed by the ANS. Although this 
procedure is somewhat time consuming, this research shows that these patient actions 
give enhanced screening ofCHD and the presence ofDM. 
The patient HR is determined from the ECG. Specifically, Lead II Einthoven bipolar 
positions are used to maximise the R-wave of the QRS complex in the ECG and require 
only three electrode connections to the patient. The R-waves are detected using a 
secant-maximum slope, peak detector and the patient HR is computed as the time 
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interval between each R-wave. Fluctuations in the beat-to-beat patient HR define the 
HRV. Since the HR is controlled by the ANS, a measure of the HRV provides 
information about the sympathetic and parasympathetic cardiovascular control 
mechanisms and indexes possible damage due to CHD or DAN. Signal processing 
algorithms were investigated and applied to the patient HRV signal in order to 
determine which algorithms best distinguish between diseased and normal patients. 
These analyses were time based, such as the standard deviation, frequency based, such 
as the PSD, and time-frequency based, such as the STFT and WT. Each of these 
analyses were applied to both the 30 minute HRV signal and indexed to 5 minute 
intervals conesponding to the patient actions. Furthennore, additional analyses were 
investigated and applied to the patient respiration and ABP signals in order to research 
if additional physiological information provides for enhanced patient screening of 
disease. Lastly, two data fusion analyses were researched. The inter-breath algorithm 
analysed the change in the HR between breaths. When applied to a normal patient, the 
inter-breath algorithm proved that, in general, the patient HR lowers between breaths; 
however, it was also determined that the measurement precision was unacceptable high 
in order to screen the patient condition. The other data fusion analysis was the QA 
interval which is a measure of the transit time between the start of the bioelectrical QRS 
complex and initial rise in ABP. When used as a basis for classification of the patient 
condition, the QA interval was also determined to be a poor feature for screening the 
presence of DM and CHD in a patient. 
The medical statistics of sensitivity, specificity, positive predictive value and negative 
predictive value were used to compare classifiers based upon the analyses features. The 
initial screening employed a nearest-neighbour classifier using supervised learning and 
through this research, it was determined that the PSD and HF estimated by the STFT or 
WT gave the best basis for screening the presence ofDM and CHD. The STFT and WT 
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based features gave the best classification as these analyses decomposed the patient 
HRV in various frequency ranges of interest while preserving the time events of the 
patient actions. In other words, these time-frequency analyses allowed the classifier to 
correlate spectrum changes in the HRV signal against actions performed by the patient, 
which gave enhanced screening. Although the WT gives multiple-higher resolutions for 
the time and frequency domains, the classification results compared to the uniform 
resolutions of the STFT. This likely due to the fact that each analysis used 5 minute 
averages; even though the WT is able to give a much higher time resolution. 
Based upon these initial results of this new methodology, further investigation is 
warranted in order to statistically prove the benefits of this clinical screening for DM 
and CHD over traditional blood-fasting and exercise ECG tests. These results are 
encouraging, especially for the screening of DM, which may be used to index the 
progression of DAN. However, the sample set of patients with known conditions was 
small due to the complex task of traditional laboratory testing for DM and CHD. The 
diagnosis of CHD was found to be not as precise as that for the DM, but does provide a 
new clinical tool for quick screening, which is far cheaper than angiography and less 
complicated than the exercise ECG. In view of recent studies, this methodology may 
provide enhanced detection of CHD over that of the exercise ECG test. 
7.2. Original Contributions 
In researching the development the clinical DAQ system, the author extensively 
investigated physiological peak detection and outlier removal. A robust, secant 
differential approximation with refractory algorithm was applied to the ECG signal in 
order to remove the effects of baseline wander, reduce higher frequency noise, avoid T-
wave detection and enhance the presence of the R-wave. This allowed for precise 
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measurement of the beat-to-beat HRV, and thus, the HRV signal. Even so, it was found 
that the HRV signal is greatly affected by ectopic beats, such as PVC, and skipped beats 
and prohibits its use in screening for disease. Outlier removal was statistically 
investigated and determined to not be applicable due to the varying nature of the HRV 
signal. Instead, a priori physiological information was used in order to determine outlier 
limits for individual samples of the HRV signal. 
More importantly, this research proved that a 30-minute HRV signal is able to screen 
for the presence of DM and CHD. Per the discussions in Chapter 1, the HRV signal is 
traditionally measured over a 24 hour period, prohibiting its use in a clinical setting. 
This research shows that, when coupled with specific patient actions, a 30 minute 
sample with 6 different patient actions is sufficient to distinguish between N, DM, 
CHD, and CHDD patients. 
Lastly, this research highlights the importance of indexing the patient actions when 
classifying their condition. That is to say, analysis features that consider the time of the 
actions performed significantly better than those features that analysed the HRV signal 
as a 30 minute sample. Furthermore, although the SDNNIDX and dP/dtmaxIDX did well 
in screening for DM and CHD, respectively, the STFT and WT performed equally well 
in screening for both DM and CHD. Therefore, this research indicates that the clinical 
procedure may be simplified by acquiring only patient HRV and not the patient 
respiration and ABP. 
7.3. Further Investigation 
Foremost, additional known patient data is required for further investigation. As this is a 
funded, United Arab Emirates University study, clinical technicians are continuing to 
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acquire known patient data with a final goal of 50 N, 50 DM, 50 CHD, and 50 CHDD 
patients. Once the full number of patients is available for testing, the analyses features 
introduced in Chapters 3, 4, and 5 will be computed and again used as bases for 
classifiers that are trained using supervised learning, as in Chapter 6. Similarly, the 
screening probabilities will again be computed and compared in order to determine the 
best features for classification and screening DM and CHD. 
Additionally, it is not readily apparent that controlled breathing by patients evokes a 
response significantly different than having the patient stand and sit/squat after supine 
measurement. Removal of the controlled breathing actions greatly simplifies the 
screening procedure by reducing the patient acquisition time in half, requiring less 
computer storage and computations, and requiring less dependence upon patient 
cooperation. 
Lastly, it known that the HRV physiology is affected by gender and age. Collection of 
female data sets and con-elation of patient age will create a more robust and generalised 
clinical system for all patients. However, the task of collecting this amount and variety 
of data from patient who have laboratOlY confirmed conditions is smlliountable. 
Additionally, the progressive effect of Type II DM upon the cardiac system has never 
been indexed. Therefore, an animal study is proposed that continually monitors the 
animal ECG and activity over at least one year's time as the Type II DM progresses. 
Specifically, implantable telemetty is proposed to ensure continuous ECG recording. 
From this infomlation, the HRV and ECG PQRST complex intervals are computed and 
indexed against the progression of Type 2 DM. The data obtained from this study may 
provide early markers for DM and DM induced CHD. That will have important clinical 
diagnostic implications in screening CHD in DM patients. Clarification of the 
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mechanisms that underlie cardiac dysfunction will pave the way for the development of 
improved clinical screening and treatments. [94] 
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Appendix A: Activity Index Questionnaire 
This four level (0 to 3) index is used to give a brief indication of the patient's activity 
based on regular exercise and walking. The following flow chart is used to detelmine 
the activity index. 
Yes 
I 
Do you follow a weekly 
I Index = 3 exercise routine? 
No 
~ 
No 
Do you take walks during .I Index = 0 J I the week? 
Yes 
r 
1 or 2 
I How many times in a week J 
"' 
Index = 1 
do you take walks? 
~3 
..J Index = 2 J , 
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Appendix B: Anxiety Index Questionnaire 
This index is based on the Hospital Anxiety and Depression (HAD) scale developed by 
Zigmond and Snaith. [95] The clinic technician reads to the patient the questionnaire 
introduction and then proceeds to ask the patient which response best describes their 
current feelings and emotions. 
At the end of the questionnaire, the A numbers and D numbers are summed together as 
a patient anxiety index and depression index. 
Considering the national language of the United Arab Emirates, the questionnaire has 
been translated into Arabic, as per the permission of the publisher. 
Questionnaire Introduction 
Doctors are aware that emotions play an important part in most illnesses. If your doctor 
knows about these feelings, he will be able to help you more. 
This questionnaire is designed to help your doctor to know how you feel. Listen to each 
statement and indicate which response best describes how you are feeling. Don't take 
long to think over your replies; your immediate reaction to each item will probably be 
more accurate than a long thought out response. 
Question 
1. I feel tense or 'wound up'. 
Patient Response 
Most of the time 
A lot of the time 
From time to time, 
occasionally 
Not at all 
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Questionnaire 
Score 
A3 
A2 
Al 
AO 
2. I still enjoy the tings I used to Definitely as much DO 
enJoy. 
Note quite so much Dl 
Only a little D2 
Hardly at all D3 
3. I get a sort of frightened feeling as 
if something awful is about to VelY definitely and quite badly A3 
happen. 
Yes, but not too badly A2 
A little, but it doesn't worry me Al 
Not at all AO 
4. I can laugh and see the funny side As much as I always could DO 
of things. 
Not quite so much now Dl 
Definitely not so much now D2 
Not at all D3 
5. Worrying thoughts go through my A great deal of the time A3 
mind. 
A lot of the time A2 
From time to time, but not too Al 
often 
Only occasionally AO 
6. I feel cheerful. Not at all D3 
Not often D2 
Sometimes Dl 
Most of the time DO 
7. I can sit at ease and feel relaxed. Definitely AO 
Usually Al 
Not often A2 
Not at all A3 
8. I feel as ifI am slowed down. Nearly all the time D3 
Very often D2 
Sometimes Dl 
Not at all DO 
9. I get a sort of frightened feeling Not al all AO like 'butterflies' in the stomach. 
Occasionally Al 
Quite often A2 
Very often A3 
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10. I have lost interest in my Definitely D3 
appearance. 
I don't take so much care as I D2 
should 
I may not take quite as much Dl 
care 
I take just as much care as ever DO 
11. I feel restless as if I have to be Very much indeed A3 
on the move. 
Quite a lot A2 
Not very much Al 
Not at all AO 
12. I look forward with enjoyment to As much as ever I did DO 
things. 
Rather less than I used to do Dl 
Definitely less than I used to D2 
Hardly at all D3 
13. I get sudden feelings of panic. VelY often indeed A3 
Quite often A2 
Not very often Al 
Not at all AO 
14. I can enjoy a good book or radio Often DO 
or TV programme. 
Sometimes Dl 
Not often D2 
Very seldom D3 
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Appendix C: List of Laboratory Tests 
Abbreviation Description of the laboratory test 
Ret. # Retinopathy Index (0 = nil, 1 = back-ground, 2 = proliferative) 
Neuro. # Neuropathy Index (0 = nil, I = sensory-motor, 2 = autonomic) 
Neph. # Nephropathy Index 
(0 = nil, 1 = impaired renal function, 2 = renal failure) 
Glycaemia 
FBSI Fasting Blood Sugar 1 (1 st hour) 
FBS2 Fasting Blood Sugar 2 (2nd hour) 
FBS3 Fasting Blood Sugar 3 (3 rd hour) 
FS Insulin Fasting Serum Insulin 
HBAIC Haemoglobin Ale 
FC-Peptide Fasting C-Peptide 
UP Urinary Protein 
UMA Urinary Micro-albumin 
Lipid 
TChol Total Cholesterol 
TG Triglyceride 
HDL High Density Lipoprotein 
LDL Low Density Lipoprotein 
I 
Apo Prot. Apoproteins AI, BlOO, ell 
VLDL Very Low Density Lipoprotein 
Angiography 
Stenosis of SAN Stenosis of SAN Artery 
LVFEF Left Ventricular Ejection Fraction 
Location of D Location of Diseased Vessels 
vessel 
Stenosis of A VN Stenosis of Atrio-Ventricular (A VN) Artery 
LVEDP Left Ventricular End Diastolic Pressure 
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Appendix D: Database Structure 
2 Bytes Word specifying the number of Name data bytes followed by the patient's 
name. 
2 Bytes Word specifying the number of Telephone data bytes followed by the 
patient's number. 
2 Bytes Word specifying the number of integers in the patient information record 
Anay of word integers containing the patient infol1nation record 
Three-column anay of word integers containing physiological infom1ation, 
respiration, blood pressure, electrocardiogram, respectively. 
Appendix D.l. Patient Information Record 
1. Hospital # (lower 4 digits) 2. Sex 3. Age 
4. DM Type 5. Cigarettes per day 6. Years of cig. use 
7. Height 8. Weight 9. Hip circumference 
10. Waist circumference 11. BP supine systolic 12. BP standing systolic 
13. BP supine diastolic 14. BP standing diastolic 15. BMI 
16. Activity 17. Anxiety 18. Medication 
19. Ret. # 20. Neuro. # 21. Neph. 
22. FBSI 23. FBS2 24. FBS3 
25. FS Insulin 26. HBAIC 27. FC-Peptide 
28. UP 29. UMA 30. TChol 
31. TG 32. HDL 33. LDL 
34. Apo Prot. 35. VLDL 36. Al 
37. Stenosis of SAN 38. LVFEF 39. Location ofD vessel 
40. Stenosis of A VN 41. LVEDP 42. Date type 
43. Patient type index 44. Hospital # (2 digits) 45. Sampling frequency 
46. Number of channels (3) 47. Channell Mode 48. Channell High 
49. Channel 1 Scale 50. Channel 2 Mode 51. Channel 2 High 
: 
52. Channel 2 Scale 53. Channel 3 Mode 54. Channel 3 High 
55. Channel 3 Scale 
. 
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Appendix E: Clinical Procedure 
1. Complete part I of the patient fonn 
2. Briefly train the patient on using the breath monitor 
3. Connect ECG Lead II electrodes 
4. Connect ABP monitor 
5. Connect respiration pressure transducer 
6. Ask patient to lie quietly on the table 
7. Complete part II of the patient f01111 
8. Begin sampling 5 minutes of supine data 
Ensure the data displays conectly 
9. Ask the patient to stand quietly 
10. Begin sampling 5 minutes of standing data 
11. Ask the patient to squat/sit quietly 
12. Begin sampling 5 minutes of sitting data 
13. With patient sitting, request patient to breathe in and out according to the breath 
monitor 
14. Set the breath monitor and begin sampling 5 minutes of 9 breaths per min. 
15. Set the breath monitor and begin sampling 5 minutes of 12 breaths per min. 
16. Set the breath monitor and begin sampling 5 minutes of 15 breaths per min. 
17. Disconnect the cables and thank patient for their assistance 
18. TURN OFF THE ECG PRE-AMP (Save the battery!) 
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Appendix F: Patient Form 
PART I 
TYPE Nonnal DM CHD CHDD 
Name 
Telephone # 
Hospital # 
Nationality 
Age 
• Sex 
Medication 
Diabetes treatment 
Cigarettes per day 
Years of smoking 
Height (cm) 
Weight (Kg) 
Hip circumference (cm) 
Waist circumference (cm) 
Standing systolic BP 
Standing diastolic BP 
Notes 
PART II 
Supine systolic BP 
Supine diastolic BP 
Anxietv & D Quest' 
-
1 2 3 4 5 6 7 8 9 10 11 12 13 14 
A D A D A D A D A D A D A D 
D Total A Total 
-
Activity Index 
No Yes 
Do you follow a weekly Do you take walks How many times in a 
exercise routine? during the week? week do you take walks? 
l Yes No 1 or 2 
I I I Index = 1 Index = 3 I I Index = 0 
::::3 
.I 
, A~ I Index = 2 
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